Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Tolerance to self-antigens prevents the elimination of cancer by the immune system 1 , 2 . We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of sub...
Uloženo v:
| Vydáno v: | Nature medicine Ročník 24; číslo 5; s. 563 - 571 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
New York
Nature Publishing Group US
01.05.2018
Nature Publishing Group |
| Témata: | |
| ISSN: | 1078-8956, 1546-170X, 1546-170X |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Tolerance to self-antigens prevents the elimination of cancer by the immune system
1
,
2
. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27
+
CD45RO
–
CD8
+
T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27
+
PD-1
–
CD8
+
CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.
An IL-6/STAT3 signature and memory CD8 T cell subset in preinfusion chimeric antigen receptor–expressing T cells associate with response in patients with high-risk chronic lymphocytic leukemia. |
|---|---|
| AbstractList | Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO-CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1-CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO-CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1-CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO–CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies.An IL-6/STAT3 signature and memory CD8 T cell subset in preinfusion chimeric antigen receptor–expressing T cells associate with response in patients with high-risk chronic lymphocytic leukemia. Tolerance to self-antigens prevents the elimination of cancer by the immune system.sup.1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27.sup.+CD45RO.sup.-CD8.sup.+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27.sup.+PD-1.sup.-CD8.sup.+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. An IL-6/STAT3 signature and memory CD8 T cell subset in preinfusion chimeric antigen receptor-expressing T cells associate with response in patients with high-risk chronic lymphocytic leukemia. Tolerance to self-antigens prevents the elimination of cancer by the immune system . We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27 CD45RO CD8 T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27 PD-1 CD8 CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. Tolerance to self-antigens prevents the elimination of cancer by the immune system.sup.1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27.sup.+CD45RO.sup.-CD8.sup.+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27.sup.+PD-1.sup.-CD8.sup.+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. Tolerance to self-antigens prevents the elimination of cancer by the immune system 1 , 2 . We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27 + CD45RO – CD8 + T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27 + PD-1 – CD8 + CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. An IL-6/STAT3 signature and memory CD8 T cell subset in preinfusion chimeric antigen receptor–expressing T cells associate with response in patients with high-risk chronic lymphocytic leukemia. Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO–CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1–CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome immunological tolerance and mediate tumor rejection in patients with chronic lymphocytic leukemia (CLL). Remission was induced in a subset of subjects, but most did not respond. Comprehensive assessment of patient-derived CAR T cells to identify mechanisms of therapeutic success and failure has not been explored. We performed genomic, phenotypic and functional evaluations to identify determinants of response. Transcriptomic profiling revealed that CAR T cells from complete-responding patients with CLL were enriched in memory-related genes, including IL-6/STAT3 signatures, whereas T cells from nonresponders upregulated programs involved in effector differentiation, glycolysis, exhaustion and apoptosis. Sustained remission was associated with an elevated frequency of CD27+CD45RO- CD8+ T cells before CAR T cell generation, and these lymphocytes possessed memory-like characteristics. Highly functional CAR T cells from patients produced STAT3-related cytokines, and serum IL-6 correlated with CAR T cell expansion. IL-6/STAT3 blockade diminished CAR T cell proliferation. Furthermore, a mechanistically relevant population of CD27+PD-1CD8+ CAR T cells expressing high levels of the IL-6 receptor predicts therapeutic response and is responsible for tumor control. These findings uncover new features of CAR T cell biology and underscore the potential of using pretreatment biomarkers of response to advance immunotherapies. |
| Audience | Academic |
| Author | Orlando, Elena J. Liu, Li Levine, Bruce L. Davis, Megan M. Johnson, F. Brad Young, Regina M. Wilcox, Nicholas Zhang, Changfeng Wherry, E. John Ambrose, David E. Gupta, Minnal O’Connor, Roddy S. Wang, Yan June, Carl H. Melenhorst, J. Joseph Huang, Alexander C. Pruteanu-Malinici, Iulian Dorfmeier, Corin Kulikovskaya, Irina Bitter, Hans Boesteanu, Alina C. Lundh, Stefan Porter, David L. Frey, Noelle V. Pequignot, Edward Siegel, Donald L. Parakandi, Harit Chen, Fang Xu, Jun Gohil, Mercy Bedoya, Felipe Brogdon, Jennifer L. Lacey, Simon F. Hwang, Wei-Ting Tian, Lifeng Fraietta, Joseph A. Kassim, Sadik H. |
| AuthorAffiliation | 6 Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA 7 Division of Transfusion Medicine and Therapeutic Pathology, University of Pennsylvania, Philadelphia, PA, USA 2 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA 5 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA 1 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA 8 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3 Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA 4 Novartis Institutes for BioMedical Research, Cambridge, MA, USA |
| AuthorAffiliation_xml | – name: 7 Division of Transfusion Medicine and Therapeutic Pathology, University of Pennsylvania, Philadelphia, PA, USA – name: 6 Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA – name: 3 Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA – name: 4 Novartis Institutes for BioMedical Research, Cambridge, MA, USA – name: 2 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, USA – name: 5 Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, USA – name: 8 Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA – name: 1 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA |
| Author_xml | – sequence: 1 givenname: Joseph A. surname: Fraietta fullname: Fraietta, Joseph A. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania, Parker Institute for Cancer Immunotherapy at University of Pennsylvania – sequence: 2 givenname: Simon F. surname: Lacey fullname: Lacey, Simon F. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania, Parker Institute for Cancer Immunotherapy at University of Pennsylvania – sequence: 3 givenname: Elena J. surname: Orlando fullname: Orlando, Elena J. organization: Novartis Institutes for BioMedical Research – sequence: 4 givenname: Iulian surname: Pruteanu-Malinici fullname: Pruteanu-Malinici, Iulian organization: Novartis Institutes for BioMedical Research – sequence: 5 givenname: Mercy surname: Gohil fullname: Gohil, Mercy organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 6 givenname: Stefan surname: Lundh fullname: Lundh, Stefan organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 7 givenname: Alina C. surname: Boesteanu fullname: Boesteanu, Alina C. organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 8 givenname: Yan surname: Wang fullname: Wang, Yan organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 9 givenname: Roddy S. surname: O’Connor fullname: O’Connor, Roddy S. organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 10 givenname: Wei-Ting surname: Hwang fullname: Hwang, Wei-Ting organization: Department of Biostatistics and Epidemiology, University of Pennsylvania – sequence: 11 givenname: Edward surname: Pequignot fullname: Pequignot, Edward organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 12 givenname: David E. surname: Ambrose fullname: Ambrose, David E. organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 13 givenname: Changfeng surname: Zhang fullname: Zhang, Changfeng organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 14 givenname: Nicholas surname: Wilcox fullname: Wilcox, Nicholas organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 15 givenname: Felipe surname: Bedoya fullname: Bedoya, Felipe organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 16 givenname: Corin surname: Dorfmeier fullname: Dorfmeier, Corin organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 17 givenname: Fang surname: Chen fullname: Chen, Fang organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 18 givenname: Lifeng surname: Tian fullname: Tian, Lifeng organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 19 givenname: Harit surname: Parakandi fullname: Parakandi, Harit organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 20 givenname: Minnal surname: Gupta fullname: Gupta, Minnal organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 21 givenname: Regina M. surname: Young fullname: Young, Regina M. organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 22 givenname: F. Brad orcidid: 0000-0002-7443-7227 surname: Johnson fullname: Johnson, F. Brad organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania – sequence: 23 givenname: Irina surname: Kulikovskaya fullname: Kulikovskaya, Irina organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 24 givenname: Li surname: Liu fullname: Liu, Li organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 25 givenname: Jun orcidid: 0000-0001-6969-0693 surname: Xu fullname: Xu, Jun organization: Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 26 givenname: Sadik H. surname: Kassim fullname: Kassim, Sadik H. organization: Novartis Institutes for BioMedical Research – sequence: 27 givenname: Megan M. surname: Davis fullname: Davis, Megan M. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 28 givenname: Bruce L. orcidid: 0000-0001-6971-8465 surname: Levine fullname: Levine, Bruce L. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania – sequence: 29 givenname: Noelle V. surname: Frey fullname: Frey, Noelle V. organization: Center for Cellular Immunotherapies, University of Pennsylvania, Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania – sequence: 30 givenname: Donald L. surname: Siegel fullname: Siegel, Donald L. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania, Division of Transfusion Medicine and Therapeutic Pathology, University of Pennsylvania – sequence: 31 givenname: Alexander C. surname: Huang fullname: Huang, Alexander C. organization: Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Department of Microbiology, Perelman School of Medicine, University of Pennsylvania – sequence: 32 givenname: E. John surname: Wherry fullname: Wherry, E. John organization: Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Department of Microbiology, Perelman School of Medicine, University of Pennsylvania – sequence: 33 givenname: Hans surname: Bitter fullname: Bitter, Hans organization: Novartis Institutes for BioMedical Research – sequence: 34 givenname: Jennifer L. surname: Brogdon fullname: Brogdon, Jennifer L. organization: Novartis Institutes for BioMedical Research – sequence: 35 givenname: David L. surname: Porter fullname: Porter, David L. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Division of Hematology-Oncology, Department of Internal Medicine, University of Pennsylvania – sequence: 36 givenname: Carl H. orcidid: 0000-0003-0241-3557 surname: June fullname: June, Carl H. organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania, Parker Institute for Cancer Immunotherapy at University of Pennsylvania – sequence: 37 givenname: J. Joseph surname: Melenhorst fullname: Melenhorst, J. Joseph email: mej@upenn.edu organization: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Center for Cellular Immunotherapies, University of Pennsylvania, Parker Institute for Cancer Immunotherapy at University of Pennsylvania |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29713085$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNk0tv1DAUhSNURB_wA9igSEioXaRc52VnU2k05VGpUqVSEDvL49xMXBI72A5iNvx2HKalnWqoUBax4--c5Obcux_taKMxil4SOCaQsbcuJ0VFEiAsASCQkCfRHinyMiEUvu6ENVCWsKood6N9564BIIOiehbtphUlGbBiL_p1ih5tr7TQ3sWmiS26wWiHsdD1tFHOCy0x9iaen5Iqlq3q0SoZzr1aog6MxMEbGx_OZ5dH8VUsseti36IVw2pylK01Ogi6VT-0Rq78tMbxG_ZKPI-eNqJz-OLmfhB9fv_uav4xOb_4cDafnSeSQuoTUlcNrWsk1QIpa-pKFAIWQsimhIZVkImU5gyzPIU0L0sKCKRYwCIvWfhDaZodRCdr32Fc9FhL1N6Kjg9W9cKuuBGKb55o1fKl-cFLQmhJsmBweGNgzfcRnee9clOlQqMZHU8hyzJGGJvQ1w_QazNaHcrjac7KMoUiZ49SkNGQFBTlHbUUHXKlGxO-Tk6v5rOCpkVJ2B-vZAsVwgkZdKFlGhUeb_DHW_hw1SETuVVwtCEIjMeffilG5_jZp8v_Zy--bLJv7rEtis63znSjV6EFN8FX9_P7G9xtIweArgFpjXMWGy6VF5NPKE11nACfRoavR4aHkeHTyHASlOSB8tb8MU261rjA6iXau_D-LfoNMz8i9Q |
| CitedBy_id | crossref_primary_10_1158_0008_5472_CAN_19_3685 crossref_primary_10_1182_blood_2020010462 crossref_primary_10_1038_s41467_023_41282_x crossref_primary_10_1182_bloodadvances_2024013209 crossref_primary_10_1002_mco2_6 crossref_primary_10_1016_j_tranon_2024_102023 crossref_primary_10_3389_fimmu_2022_873789 crossref_primary_10_1007_s12032_024_02399_1 crossref_primary_10_1016_j_jcyt_2020_01_014 crossref_primary_10_1002_cyto_a_24678 crossref_primary_10_1016_j_immuni_2024_08_014 crossref_primary_10_1038_s41540_024_00335_7 crossref_primary_10_1172_JCI125423 crossref_primary_10_3389_fimmu_2023_1183698 crossref_primary_10_3390_cancers13133236 crossref_primary_10_1038_s41409_022_01866_5 crossref_primary_10_1158_2159_8290_CD_24_0841 crossref_primary_10_1016_j_jcyt_2025_04_068 crossref_primary_10_1038_s41598_024_72392_1 crossref_primary_10_3389_fimmu_2025_1592574 crossref_primary_10_1038_s41392_023_01659_2 crossref_primary_10_1038_s41573_019_0020_9 crossref_primary_10_1038_s41467_024_49059_6 crossref_primary_10_1016_j_omtm_2020_06_024 crossref_primary_10_1016_j_jaip_2021_10_037 crossref_primary_10_3389_fimmu_2023_1159337 crossref_primary_10_3390_ijms25010615 crossref_primary_10_3389_fimmu_2019_01719 crossref_primary_10_3389_fimmu_2019_02809 crossref_primary_10_1136_jitc_2022_006292 crossref_primary_10_3390_ijms241210374 crossref_primary_10_3389_fimmu_2023_1206441 crossref_primary_10_3389_fimmu_2025_1635159 crossref_primary_10_1038_s43018_025_00940_3 crossref_primary_10_3390_cancers12082175 crossref_primary_10_1016_j_critrevonc_2020_103161 crossref_primary_10_1016_j_exphem_2022_02_001 crossref_primary_10_1016_j_jcyt_2025_02_003 crossref_primary_10_3390_ijms25168662 crossref_primary_10_1007_s11684_022_0972_8 crossref_primary_10_1080_14728222_2025_2545845 crossref_primary_10_3389_fimmu_2020_570672 crossref_primary_10_3389_fimmu_2022_1064339 crossref_primary_10_3389_fimmu_2023_1185618 crossref_primary_10_3389_fbioe_2021_761218 crossref_primary_10_1016_j_jtct_2023_06_018 crossref_primary_10_62347_WDWE6603 crossref_primary_10_1007_s10555_024_10228_0 crossref_primary_10_3390_ijms25042416 crossref_primary_10_3390_ijms20246223 crossref_primary_10_1186_s12943_024_01938_8 crossref_primary_10_1007_s12254_021_00755_9 crossref_primary_10_1038_s41598_020_74772_9 crossref_primary_10_1126_scitranslmed_abk1900 crossref_primary_10_1158_2159_8290_CD_19_0945 crossref_primary_10_1080_10428194_2020_1755857 crossref_primary_10_1007_s00011_021_01470_1 crossref_primary_10_1016_j_coi_2019_03_007 crossref_primary_10_3389_fimmu_2018_02166 crossref_primary_10_3389_fonc_2021_626818 crossref_primary_10_3390_cancers14215276 crossref_primary_10_1016_j_revmed_2018_12_002 crossref_primary_10_1007_s12672_023_00793_1 crossref_primary_10_1080_17474086_2022_2084068 crossref_primary_10_1158_2326_6066_CIR_22_0685 crossref_primary_10_1182_blood_2023023210 crossref_primary_10_1038_s41467_025_60074_z crossref_primary_10_3390_ijms221910828 crossref_primary_10_1007_s00262_020_02484_0 crossref_primary_10_2147_IJN_S390720 crossref_primary_10_1136_jitc_2023_008723 crossref_primary_10_3390_cells11142176 crossref_primary_10_1002_adhm_202002200 crossref_primary_10_1038_s41591_022_01799_y crossref_primary_10_3390_ijms252313157 crossref_primary_10_1016_j_cels_2024_03_004 crossref_primary_10_3389_fonc_2023_1288172 crossref_primary_10_1182_bloodadvances_2020002394 crossref_primary_10_3390_ijms21103525 crossref_primary_10_1080_10428194_2024_2449214 crossref_primary_10_3389_fimmu_2024_1426418 crossref_primary_10_1016_j_intimp_2024_112317 crossref_primary_10_1016_j_it_2019_11_004 crossref_primary_10_1146_annurev_pharmtox_031720_102211 crossref_primary_10_1016_j_omto_2023_05_007 crossref_primary_10_1016_j_jcyt_2022_05_001 crossref_primary_10_1007_s11684_023_1010_1 crossref_primary_10_3389_fbioe_2019_00131 crossref_primary_10_3390_cancers12123837 crossref_primary_10_1016_j_jpba_2023_115680 crossref_primary_10_1016_j_stem_2023_02_009 crossref_primary_10_1186_s12967_022_03531_3 crossref_primary_10_1186_s40164_024_00536_0 crossref_primary_10_3389_fimmu_2022_1027385 crossref_primary_10_1111_imr_12772 crossref_primary_10_1038_s43018_024_00749_6 crossref_primary_10_1111_imr_12773 crossref_primary_10_1158_2326_6066_CIR_23_0677 crossref_primary_10_1016_j_jcis_2024_06_102 crossref_primary_10_1111_imr_12774 crossref_primary_10_1126_sciadv_adv4937 crossref_primary_10_1016_j_drup_2021_100787 crossref_primary_10_3390_cancers13081926 crossref_primary_10_1038_s41577_019_0223_7 crossref_primary_10_1016_j_ebiom_2022_103941 crossref_primary_10_1038_s41573_019_0051_2 crossref_primary_10_1186_s12967_024_04990_6 crossref_primary_10_1136_jitc_2020_002328 crossref_primary_10_3389_fimmu_2021_609421 crossref_primary_10_1016_j_retram_2019_12_001 crossref_primary_10_1016_j_ymthe_2024_03_033 crossref_primary_10_1111_imr_12768 crossref_primary_10_3389_fimmu_2020_577027 crossref_primary_10_1016_j_celrep_2024_114065 crossref_primary_10_1186_s12967_022_03797_7 crossref_primary_10_1136_jitc_2022_005189 crossref_primary_10_1186_s12929_024_01006_9 crossref_primary_10_1186_s13045_020_00910_5 crossref_primary_10_1038_s41590_022_01224_z crossref_primary_10_1186_s40164_019_0155_8 crossref_primary_10_1038_s41467_023_43790_2 crossref_primary_10_1073_pnas_2317735121 crossref_primary_10_1038_s41591_022_01960_7 crossref_primary_10_1002_smll_202302812 crossref_primary_10_1084_jem_20201574 crossref_primary_10_1038_s41586_024_07242_1 crossref_primary_10_3389_fimmu_2021_724211 crossref_primary_10_1002_advs_202400702 crossref_primary_10_1136_jitc_2021_003354 crossref_primary_10_3389_fimmu_2021_782775 crossref_primary_10_1016_j_jtct_2021_05_027 crossref_primary_10_3389_fimmu_2020_01217 crossref_primary_10_1007_s00108_021_01056_3 crossref_primary_10_1182_bloodadvances_2019000703 crossref_primary_10_1016_j_jcyt_2021_08_007 crossref_primary_10_3390_cancers14071715 crossref_primary_10_5858_arpa_2019_0632_CP crossref_primary_10_1016_j_tibtech_2024_09_013 crossref_primary_10_1111_cas_14638 crossref_primary_10_1136_jitc_2021_004446 crossref_primary_10_1016_j_cell_2023_08_013 crossref_primary_10_1038_s41586_023_05707_3 crossref_primary_10_1038_s41588_023_01554_0 crossref_primary_10_1016_j_gpb_2019_03_002 crossref_primary_10_1038_s41378_022_00422_x crossref_primary_10_1080_2162402X_2020_1866287 crossref_primary_10_1126_sciadv_adv6902 crossref_primary_10_1016_j_addr_2022_114301 crossref_primary_10_1631_jzus_B2200256 crossref_primary_10_1038_s41388_022_02455_y crossref_primary_10_1007_s00262_023_03418_2 crossref_primary_10_1016_j_addr_2019_01_007 crossref_primary_10_3390_ijms26178747 crossref_primary_10_1016_S2352_3026_20_30284_2 crossref_primary_10_1371_journal_pone_0247701 crossref_primary_10_1038_s41409_025_02637_8 crossref_primary_10_1136_jitc_2024_008876 crossref_primary_10_1182_blood_2021011597 crossref_primary_10_3389_fimmu_2020_01689 crossref_primary_10_1016_j_cmet_2023_02_013 crossref_primary_10_1016_j_it_2019_10_006 crossref_primary_10_1038_s41423_025_01304_8 crossref_primary_10_1016_j_omtm_2021_10_009 crossref_primary_10_1016_j_jaci_2020_07_001 crossref_primary_10_1016_j_omtm_2021_10_006 crossref_primary_10_1016_j_jcyt_2022_03_013 crossref_primary_10_1016_S2352_3026_24_00273_4 crossref_primary_10_1172_JCI145459 crossref_primary_10_1016_j_omto_2020_08_009 crossref_primary_10_1038_s41467_021_23331_5 crossref_primary_10_1038_s41590_022_01219_w crossref_primary_10_1158_2159_8290_CD_21_1683 crossref_primary_10_46989_001c_88382 crossref_primary_10_3390_ijms22094590 crossref_primary_10_1007_s15004_019_6365_8 crossref_primary_10_1172_JCI150807 crossref_primary_10_1016_j_ccell_2020_09_019 crossref_primary_10_1016_j_canlet_2024_216871 crossref_primary_10_1186_s12943_022_01559_z crossref_primary_10_1038_s41590_023_01685_w crossref_primary_10_1038_s41598_022_10320_x crossref_primary_10_1038_s41590_024_02042_1 crossref_primary_10_3390_cancers13184681 crossref_primary_10_1002_bit_27882 crossref_primary_10_1136_jitc_2024_009949 crossref_primary_10_1007_s00262_022_03163_y crossref_primary_10_3389_fimmu_2021_780145 crossref_primary_10_3390_ijms23136931 crossref_primary_10_1002_cpt_2986 crossref_primary_10_1186_s40164_025_00701_z crossref_primary_10_1002_cpt_2509 crossref_primary_10_1084_jem_20230903 crossref_primary_10_1016_j_bbmt_2019_11_027 crossref_primary_10_1172_JCI128743 crossref_primary_10_1016_j_biotechadv_2021_107760 crossref_primary_10_1038_s41467_023_36126_7 crossref_primary_10_1038_s41568_024_00723_5 crossref_primary_10_1016_j_dmpk_2024_101003 crossref_primary_10_1038_s41587_023_01687_x crossref_primary_10_1111_imr_12794 crossref_primary_10_1038_s41591_023_02496_0 crossref_primary_10_1016_j_bcp_2022_114970 crossref_primary_10_1007_s12185_024_03794_0 crossref_primary_10_3390_cancers14041078 crossref_primary_10_1186_s12967_025_06416_3 crossref_primary_10_1016_j_cryobiol_2020_07_009 crossref_primary_10_1177_0300891620960223 crossref_primary_10_1002_advs_202309053 crossref_primary_10_1080_14712598_2021_1857361 crossref_primary_10_1259_bjr_20210098 crossref_primary_10_1016_j_hoc_2025_05_011 crossref_primary_10_1002_INMD_20230047 crossref_primary_10_1056_NEJMra1908213 crossref_primary_10_1016_j_ymthe_2021_10_004 crossref_primary_10_1158_2159_8290_CD_22_1276 crossref_primary_10_1038_s41586_024_07300_8 crossref_primary_10_1182_blood_2020009432 crossref_primary_10_1016_j_jtct_2021_10_005 crossref_primary_10_1186_s12967_019_02206_w crossref_primary_10_3389_fimmu_2023_1187850 crossref_primary_10_1016_j_jtct_2021_10_001 crossref_primary_10_1093_nar_gkae534 crossref_primary_10_1038_s41423_023_01120_y crossref_primary_10_1038_s41467_019_11157_1 crossref_primary_10_1016_j_jcyt_2019_12_004 crossref_primary_10_2147_ITT_S474659 crossref_primary_10_3389_fbioe_2021_598087 crossref_primary_10_3389_fimmu_2021_640082 crossref_primary_10_1007_s00262_020_02612_w crossref_primary_10_1182_blood_2020009206 crossref_primary_10_1080_1744666X_2024_2349738 crossref_primary_10_3389_fimmu_2018_02740 crossref_primary_10_1016_j_trecan_2025_08_014 crossref_primary_10_3390_cancers11121832 crossref_primary_10_1053_j_seminhematol_2023_01_002 crossref_primary_10_1038_s41467_025_60394_0 crossref_primary_10_1136_jitc_2023_007002 crossref_primary_10_3390_cancers16010039 crossref_primary_10_1172_JCI159402 crossref_primary_10_1007_s40291_023_00680_z crossref_primary_10_1038_s41375_022_01649_3 crossref_primary_10_1038_s41421_023_00625_0 crossref_primary_10_1136_jitc_2024_010709 crossref_primary_10_1200_JCO_24_02424 crossref_primary_10_3390_cancers17020268 crossref_primary_10_1007_s11864_019_0619_4 crossref_primary_10_1007_s11864_023_01140_w crossref_primary_10_4049_jimmunol_2000954 crossref_primary_10_3389_fimmu_2023_1270843 crossref_primary_10_1111_bjh_17191 crossref_primary_10_1182_bloodadvances_2022007317 crossref_primary_10_1158_2159_8290_CD_19_0073 crossref_primary_10_1038_s41540_024_00355_3 crossref_primary_10_3389_fimmu_2021_718621 crossref_primary_10_1016_j_ccell_2020_08_001 crossref_primary_10_1016_j_imlet_2019_10_002 crossref_primary_10_1016_S2665_9913_24_00377_1 crossref_primary_10_1186_s13045_018_0676_3 crossref_primary_10_1038_d41586_018_07728_9 crossref_primary_10_3390_cancers15061813 crossref_primary_10_1038_s41375_025_02518_5 crossref_primary_10_1016_j_jcis_2025_137339 crossref_primary_10_1007_s40263_018_0582_9 crossref_primary_10_3389_fimmu_2025_1597888 crossref_primary_10_1136_jitc_2024_009743 crossref_primary_10_1016_j_biopha_2025_117987 crossref_primary_10_1111_bjh_17175 crossref_primary_10_1186_s40425_018_0460_5 crossref_primary_10_1111_cas_15541 crossref_primary_10_1016_j_tips_2020_11_004 crossref_primary_10_1016_j_ymthe_2024_01_030 crossref_primary_10_1080_10428194_2021_1913146 crossref_primary_10_1038_s41467_025_59021_9 crossref_primary_10_3390_cancers12092567 crossref_primary_10_1172_JCI120775 crossref_primary_10_3389_fonc_2021_664421 crossref_primary_10_1038_s41375_020_0874_1 crossref_primary_10_1097_PPO_0000000000000506 crossref_primary_10_2217_fon_2021_0089 crossref_primary_10_1016_j_biotechadv_2024_108405 crossref_primary_10_1007_s00277_020_04020_7 crossref_primary_10_3390_cells10123497 crossref_primary_10_1007_s11060_019_03311_y crossref_primary_10_1016_j_ccell_2022_04_001 crossref_primary_10_1016_j_ymthe_2020_07_018 crossref_primary_10_1016_j_ymthe_2020_07_017 crossref_primary_10_1016_j_matt_2021_09_027 crossref_primary_10_1016_j_cell_2024_08_029 crossref_primary_10_1007_s00108_021_01041_w crossref_primary_10_1038_s41392_024_02079_6 crossref_primary_10_1111_bjh_17397 crossref_primary_10_1038_s41551_024_01315_2 crossref_primary_10_1038_s41375_023_01905_0 crossref_primary_10_3389_fimmu_2023_1268698 crossref_primary_10_1016_j_molmed_2018_06_007 crossref_primary_10_1158_2326_6066_CIR_21_0253 crossref_primary_10_1186_s40779_024_00556_1 crossref_primary_10_1007_s40259_019_00368_z crossref_primary_10_3390_cells10113208 crossref_primary_10_1007_s00018_024_05412_y crossref_primary_10_1016_j_omton_2024_200897 crossref_primary_10_1038_s41568_019_0224_7 crossref_primary_10_1182_blood_2021012714 crossref_primary_10_1007_s00262_023_03618_w crossref_primary_10_1016_j_jconrel_2023_05_016 crossref_primary_10_3390_cancers14225576 crossref_primary_10_1016_j_omtm_2020_09_011 crossref_primary_10_1007_s12272_019_01136_x crossref_primary_10_1182_bloodadvances_2022008697 crossref_primary_10_1038_s41392_023_01642_x crossref_primary_10_3389_fphar_2021_724306 crossref_primary_10_1002_ajh_26586 crossref_primary_10_1038_s41586_019_1805_z crossref_primary_10_1039_D1RA05638G crossref_primary_10_1097_PPO_0000000000000532 crossref_primary_10_1007_s40291_023_00671_0 crossref_primary_10_1097_CCO_0000000000000671 crossref_primary_10_1002_advs_202103508 crossref_primary_10_1016_j_omto_2023_07_003 crossref_primary_10_3389_fimmu_2022_1050522 crossref_primary_10_1016_j_omtm_2018_12_009 crossref_primary_10_3390_ijms23052878 crossref_primary_10_1038_s41590_023_01665_0 crossref_primary_10_3389_fimmu_2023_1186383 crossref_primary_10_1182_blood_2024025536 crossref_primary_10_1016_j_omtm_2023_07_012 crossref_primary_10_1186_s13073_023_01256_6 crossref_primary_10_1038_s41596_021_00510_8 crossref_primary_10_1097_PPO_0000000000000512 crossref_primary_10_1097_PPO_0000000000000513 crossref_primary_10_3389_fimmu_2024_1378944 crossref_primary_10_1016_j_smim_2023_101840 crossref_primary_10_1172_jci_insight_193048 crossref_primary_10_1182_bloodadvances_2021005883 crossref_primary_10_1016_j_biotechadv_2024_108434 crossref_primary_10_1080_17474086_2021_1935853 crossref_primary_10_3389_fonc_2021_719140 crossref_primary_10_3389_fonc_2022_944248 crossref_primary_10_1016_j_intimp_2023_110528 crossref_primary_10_3322_caac_21702 crossref_primary_10_1182_bloodadvances_2020002783 crossref_primary_10_3389_fimmu_2024_1432799 crossref_primary_10_1073_pnas_2104758118 crossref_primary_10_1186_s13063_021_05121_y crossref_primary_10_3390_ijms25126324 crossref_primary_10_1158_2326_6066_CIR_24_0857 crossref_primary_10_3390_cancers14030497 crossref_primary_10_1080_2162402X_2020_1752592 crossref_primary_10_1016_j_omto_2021_03_001 crossref_primary_10_3390_cells11040661 crossref_primary_10_1016_j_omto_2021_03_003 crossref_primary_10_1038_s41586_024_07862_7 crossref_primary_10_1002_ijc_33002 crossref_primary_10_1186_s12943_020_01258_7 crossref_primary_10_3390_biom12091296 crossref_primary_10_1038_s41587_019_0398_2 crossref_primary_10_1093_jimmun_vkaf182 crossref_primary_10_3389_fimmu_2021_780442 crossref_primary_10_1007_s11912_023_01454_w crossref_primary_10_1080_1744666X_2024_2380894 crossref_primary_10_1038_s41598_024_72016_8 crossref_primary_10_1084_jem_20240258 crossref_primary_10_1186_s13059_023_03120_7 crossref_primary_10_1016_j_jcyt_2020_05_004 crossref_primary_10_3390_biomedicines11041107 crossref_primary_10_3389_fimmu_2019_01595 crossref_primary_10_1182_blood_2020005362 crossref_primary_10_1111_bjh_16260 crossref_primary_10_1038_s41467_020_17175_8 crossref_primary_10_1136_jitc_2023_008174 crossref_primary_10_1038_s41408_023_00958_9 crossref_primary_10_1016_j_omtm_2021_03_011 crossref_primary_10_1136_jitc_2024_009367 crossref_primary_10_1080_10428194_2024_2325188 crossref_primary_10_1002_cyto_a_24900 crossref_primary_10_3389_fonc_2020_01243 crossref_primary_10_1126_sciimmunol_adk2954 crossref_primary_10_1158_2159_8290_CD_18_1314 crossref_primary_10_3390_cancers13205154 crossref_primary_10_1016_j_xcrm_2025_102353 crossref_primary_10_1038_s41568_023_00615_0 crossref_primary_10_1038_s41375_021_01324_z crossref_primary_10_1182_blood_2024024893 crossref_primary_10_1038_s41577_018_0119_y crossref_primary_10_3390_ijms26020805 crossref_primary_10_1002_cti2_1268 crossref_primary_10_1002_jha2_70006 crossref_primary_10_1016_j_beha_2020_101141 crossref_primary_10_1136_jitc_2022_005878 crossref_primary_10_1158_2159_8290_CD_20_1243 crossref_primary_10_3389_fimmu_2022_1039929 crossref_primary_10_1016_j_engmed_2024_100038 crossref_primary_10_1016_j_jtct_2023_04_007 crossref_primary_10_1158_2159_8290_CD_20_1248 crossref_primary_10_1016_j_annonc_2025_03_011 crossref_primary_10_1038_s41409_020_01000_3 crossref_primary_10_1038_s41596_019_0249_0 crossref_primary_10_1038_s41577_019_0140_9 crossref_primary_10_1016_j_metabol_2025_156375 crossref_primary_10_1016_j_cell_2021_11_016 crossref_primary_10_1002_adhm_202502930 crossref_primary_10_3390_cells11071140 crossref_primary_10_1158_1078_0432_CCR_23_3759 crossref_primary_10_1007_s11899_020_00602_4 crossref_primary_10_1038_s41598_022_06830_3 crossref_primary_10_1007_s11684_025_1130_x crossref_primary_10_1016_j_intimp_2023_110974 crossref_primary_10_1016_j_isci_2025_113234 crossref_primary_10_3389_fonc_2025_1591360 crossref_primary_10_1111_bjh_19751 crossref_primary_10_1126_scitranslmed_abg6986 crossref_primary_10_3390_mps8050108 crossref_primary_10_1016_j_cllc_2021_08_011 crossref_primary_10_1038_s41591_023_02785_8 crossref_primary_10_1158_0008_5472_CAN_22_2155 crossref_primary_10_1002_cti2_1282 crossref_primary_10_1182_blood_2018885863 crossref_primary_10_1016_j_jcyt_2025_05_006 crossref_primary_10_1016_j_currproblcancer_2021_100827 crossref_primary_10_1016_j_biomaterials_2019_119265 crossref_primary_10_1126_science_aay2790 crossref_primary_10_1158_1078_0432_CCR_18_0758 crossref_primary_10_3390_jcm9113577 crossref_primary_10_1111_imcb_12545 crossref_primary_10_1182_blood_2018_01_826008 crossref_primary_10_3389_fimmu_2021_683332 crossref_primary_10_1016_j_ctarc_2021_100494 crossref_primary_10_1016_j_apmt_2021_101036 crossref_primary_10_1136_jitc_2022_006582 crossref_primary_10_1038_s44222_024_00219_9 crossref_primary_10_1038_s41551_019_0486_0 crossref_primary_10_1080_1547691X_2024_2345158 crossref_primary_10_1172_JCI138473 crossref_primary_10_1177_1758835920962963 crossref_primary_10_1080_17568919_2025_2546774 crossref_primary_10_3389_fimmu_2023_1285406 crossref_primary_10_1080_2162402X_2020_1747349 crossref_primary_10_1016_j_tranon_2022_101342 crossref_primary_10_1111_bjh_17551 crossref_primary_10_1158_2159_8290_CD_20_0779 crossref_primary_10_1016_j_blre_2021_100884 crossref_primary_10_1016_j_retram_2021_103320 crossref_primary_10_3390_ijms23063374 crossref_primary_10_1182_blood_2022016226 crossref_primary_10_1016_j_ymthe_2025_07_045 crossref_primary_10_1111_imm_13642 crossref_primary_10_3389_fimmu_2021_600829 crossref_primary_10_1136_jitc_2019_000471 crossref_primary_10_1200_EDBK_389860 crossref_primary_10_1016_j_ymthe_2020_09_015 crossref_primary_10_32604_or_2024_048564 crossref_primary_10_1016_j_ccell_2022_06_001 crossref_primary_10_1038_s41375_025_02697_1 crossref_primary_10_1007_s12185_022_03398_6 crossref_primary_10_1158_1078_0432_CCR_19_0916 crossref_primary_10_1016_j_omtm_2018_10_006 crossref_primary_10_1126_science_abn5647 crossref_primary_10_1111_sji_13352 crossref_primary_10_1186_s12967_023_04019_4 crossref_primary_10_1111_bcp_14281 crossref_primary_10_1038_s41591_024_02875_1 crossref_primary_10_3390_cells11111854 crossref_primary_10_1002_cti2_70016 crossref_primary_10_1186_s13045_020_00947_6 crossref_primary_10_3389_fonc_2021_794183 crossref_primary_10_1073_pnas_1808320115 crossref_primary_10_1172_JCI162593 crossref_primary_10_1016_j_clml_2021_10_003 crossref_primary_10_3389_fimmu_2021_684642 crossref_primary_10_1016_j_semcancer_2019_12_002 crossref_primary_10_3389_fimmu_2023_1303935 crossref_primary_10_1038_s41467_022_31035_7 crossref_primary_10_1038_s41422_022_00721_y crossref_primary_10_1186_s12967_023_04117_3 crossref_primary_10_3389_fimmu_2025_1516946 crossref_primary_10_1089_hum_2022_090 crossref_primary_10_1146_annurev_cancerbio_062822_023316 crossref_primary_10_1016_j_ymthe_2020_09_040 crossref_primary_10_1016_j_blre_2025_101272 crossref_primary_10_3389_fimmu_2023_1274781 crossref_primary_10_1016_j_omtm_2024_101250 crossref_primary_10_1038_s41467_025_59789_w crossref_primary_10_1186_s40164_023_00438_7 crossref_primary_10_1158_2159_8290_CD_20_0756 crossref_primary_10_1373_clinchem_2016_258988 crossref_primary_10_1172_JCI130144 crossref_primary_10_1186_s40164_024_00553_z crossref_primary_10_1016_j_jtct_2024_11_008 crossref_primary_10_1016_j_omtm_2025_101553 crossref_primary_10_1038_s41467_022_32866_0 crossref_primary_10_1016_j_omton_2025_200977 crossref_primary_10_1002_1878_0261_13691 crossref_primary_10_1002_ajh_27098 crossref_primary_10_1007_s12185_022_03365_1 crossref_primary_10_3390_ijms21010204 crossref_primary_10_1182_bloodadvances_2020002309 crossref_primary_10_1038_s41392_019_0070_9 crossref_primary_10_3390_cells9061485 crossref_primary_10_3389_fimmu_2020_581116 crossref_primary_10_1158_2643_3230_BCD_24_0203 crossref_primary_10_1016_j_stem_2022_06_014 crossref_primary_10_1002_hon_2672 crossref_primary_10_1016_j_jcyt_2022_07_009 crossref_primary_10_1182_bloodadvances_2019000466 crossref_primary_10_2478_raon_2022_0049 crossref_primary_10_1038_s41467_025_60980_2 crossref_primary_10_3389_fimmu_2022_1052717 crossref_primary_10_1016_j_cell_2022_03_004 crossref_primary_10_1186_s12967_019_2001_5 crossref_primary_10_3389_fimmu_2024_1335424 crossref_primary_10_1038_s41467_019_14081_6 crossref_primary_10_1080_10428194_2024_2430703 crossref_primary_10_1186_s12964_023_01354_3 crossref_primary_10_1158_2326_6066_CIR_24_0204 crossref_primary_10_1038_s41551_021_00698_w crossref_primary_10_1158_2159_8290_CD_20_1677 crossref_primary_10_1172_JCI178949 crossref_primary_10_1186_s12967_024_05462_7 crossref_primary_10_1002_adma_202103258 crossref_primary_10_1016_j_lfs_2022_121016 crossref_primary_10_1016_j_hoc_2023_07_002 crossref_primary_10_1111_bjh_18831 crossref_primary_10_3390_ijms23010405 crossref_primary_10_1016_j_hoc_2023_07_003 crossref_primary_10_1111_ejh_13964 crossref_primary_10_1182_blood_2019002121 crossref_primary_10_1016_j_jconrel_2020_07_016 crossref_primary_10_1038_s41586_021_04390_6 crossref_primary_10_1002_cam4_7375 crossref_primary_10_1182_blood_2021014492 crossref_primary_10_3350_cmh_2024_0781 crossref_primary_10_1038_s41565_024_01651_z crossref_primary_10_1186_s12967_023_04292_3 crossref_primary_10_3389_fcell_2022_1034257 crossref_primary_10_1016_j_omtm_2025_101586 crossref_primary_10_1016_j_omtm_2020_07_008 crossref_primary_10_1007_s12032_025_02923_x crossref_primary_10_1126_science_aba1786 crossref_primary_10_1136_jitc_2019_000218 crossref_primary_10_1038_s41375_021_01217_1 crossref_primary_10_3390_ph15020207 crossref_primary_10_1038_s41598_022_16616_2 crossref_primary_10_1089_hum_2022_068 crossref_primary_10_1038_s41375_019_0669_4 crossref_primary_10_3389_fimmu_2022_795164 crossref_primary_10_1182_bloodadvances_2024012563 crossref_primary_10_1172_JCI153204 crossref_primary_10_3390_ijms23063154 crossref_primary_10_1158_1078_0432_CCR_22_2293 crossref_primary_10_1016_j_ccell_2025_03_019 crossref_primary_10_1038_s41467_025_61822_x crossref_primary_10_1158_2326_6066_CIR_19_0152 crossref_primary_10_1016_j_cellimm_2025_105001 crossref_primary_10_1016_j_cellimm_2021_104436 crossref_primary_10_3389_fimmu_2020_00888 crossref_primary_10_1186_s12967_023_04329_7 crossref_primary_10_1126_scitranslmed_abh0272 crossref_primary_10_1158_2159_8290_CD_19_0813 crossref_primary_10_1158_2159_8290_CD_22_1350 crossref_primary_10_3390_cancers12082030 crossref_primary_10_1126_scitranslmed_add7900 crossref_primary_10_1021_acscentsci_2c00142 crossref_primary_10_1186_s13045_023_01470_0 crossref_primary_10_1002_cyto_a_24796 crossref_primary_10_3389_fimmu_2019_00990 crossref_primary_10_1159_000534341 crossref_primary_10_3389_fimmu_2022_904497 crossref_primary_10_1186_s12943_025_02371_1 crossref_primary_10_1146_annurev_immunol_042718_041407 crossref_primary_10_1016_j_canlet_2022_215710 crossref_primary_10_1016_j_omtm_2022_02_004 crossref_primary_10_1186_s12935_022_02778_6 crossref_primary_10_1053_j_seminhematol_2024_04_001 crossref_primary_10_3390_ijms20081903 crossref_primary_10_1016_j_bulcan_2021_09_002 crossref_primary_10_1007_s12185_020_02923_9 crossref_primary_10_1136_jitc_2021_002555 crossref_primary_10_1038_s41467_025_59904_x crossref_primary_10_1136_jitc_2023_008656 crossref_primary_10_1016_j_xphs_2020_12_015 crossref_primary_10_1136_jitc_2023_007329 crossref_primary_10_1016_j_jaci_2025_04_005 crossref_primary_10_3389_fcell_2025_1577081 crossref_primary_10_1007_s12015_023_10668_1 crossref_primary_10_1038_s41417_022_00518_6 crossref_primary_10_1016_j_omtm_2023_101139 crossref_primary_10_1038_s41392_022_01136_2 crossref_primary_10_1186_s13045_023_01492_8 crossref_primary_10_3390_cancers16162858 crossref_primary_10_1097_BS9_0000000000000068 crossref_primary_10_1016_j_immuni_2021_11_004 crossref_primary_10_1136_jitc_2023_008429 crossref_primary_10_1007_s40883_019_00124_3 crossref_primary_10_3389_fonc_2022_884782 crossref_primary_10_1016_j_addr_2022_114242 crossref_primary_10_1080_17474086_2024_2370552 crossref_primary_10_3389_fimmu_2023_1264882 crossref_primary_10_3390_cancers13112639 crossref_primary_10_1007_s15015_019_0049_y crossref_primary_10_1016_j_bbcan_2025_189284 crossref_primary_10_1093_ndt_gfae160 crossref_primary_10_3389_fimmu_2025_1655095 crossref_primary_10_1182_bloodadvances_2020004038 crossref_primary_10_3389_fimmu_2021_658314 crossref_primary_10_1158_2326_6066_CIR_22_0533 crossref_primary_10_3389_fimmu_2022_1056622 crossref_primary_10_1186_s13045_023_01504_7 crossref_primary_10_3389_fimmu_2022_840956 crossref_primary_10_1155_2021_1782728 crossref_primary_10_3390_cancers12040842 crossref_primary_10_3389_fimmu_2020_01941 crossref_primary_10_1158_1078_0432_CCR_24_0414 crossref_primary_10_1038_s41598_020_74927_8 crossref_primary_10_1056_NEJMoa2301665 crossref_primary_10_1016_j_immuni_2018_11_014 crossref_primary_10_1016_j_immuni_2024_01_011 crossref_primary_10_3390_ijms21103650 crossref_primary_10_3390_genes14051008 crossref_primary_10_1007_s00432_022_04190_z crossref_primary_10_1002_adma_201802378 crossref_primary_10_1038_s41573_023_00807_1 crossref_primary_10_1053_j_seminhematol_2024_05_002 crossref_primary_10_3389_fonc_2020_00849 crossref_primary_10_1038_s41590_020_0725_2 crossref_primary_10_3390_cancers16193339 crossref_primary_10_1016_j_biopha_2025_118308 crossref_primary_10_1007_s11912_019_0789_z crossref_primary_10_1016_j_beha_2018_07_011 crossref_primary_10_3389_fimmu_2020_01770 crossref_primary_10_1007_s11864_021_00920_6 crossref_primary_10_1158_1078_0432_CCR_22_0164 crossref_primary_10_1186_s40425_019_0529_9 crossref_primary_10_1158_0008_5472_CAN_19_1196 crossref_primary_10_1016_j_ccell_2020_05_004 crossref_primary_10_1155_2021_6616391 crossref_primary_10_1182_blood_2019003944 crossref_primary_10_1038_s41375_021_01198_1 crossref_primary_10_1158_1078_0432_CCR_21_1483 crossref_primary_10_1007_s12254_022_00818_5 crossref_primary_10_3389_fonc_2022_837531 crossref_primary_10_1016_j_bbcan_2025_189455 crossref_primary_10_1126_sciimmunol_abb9726 crossref_primary_10_3390_ijms241512317 crossref_primary_10_1002_smll_202107732 crossref_primary_10_1097_PPO_0000000000000381 crossref_primary_10_3390_ijms21082856 crossref_primary_10_1016_j_cell_2025_07_004 crossref_primary_10_1038_s41422_022_00682_2 crossref_primary_10_3389_fimmu_2018_02460 crossref_primary_10_1093_clinchem_hvad179 crossref_primary_10_3390_ijms20061283 crossref_primary_10_1182_bloodadvances_2023011992 crossref_primary_10_3389_fimmu_2022_883694 crossref_primary_10_1097_CJI_0000000000000402 crossref_primary_10_1016_j_ab_2024_115626 crossref_primary_10_1016_j_ccell_2022_09_013 crossref_primary_10_1073_pnas_2106612118 crossref_primary_10_1038_s41408_024_01193_6 crossref_primary_10_1016_j_bbcan_2024_189162 crossref_primary_10_1038_s41467_022_30860_0 crossref_primary_10_1111_bjh_17904 crossref_primary_10_1158_2326_6066_CIR_22_0333 crossref_primary_10_1136_jitc_2023_006699 crossref_primary_10_1016_j_ymthe_2025_04_006 crossref_primary_10_3390_cancers13194787 crossref_primary_10_1038_s41551_019_0512_2 crossref_primary_10_1038_s43018_021_00241_5 crossref_primary_10_1016_j_canlet_2025_217771 crossref_primary_10_1186_s40164_024_00535_1 crossref_primary_10_3389_fmolb_2020_00084 crossref_primary_10_1002_psp4_13011 crossref_primary_10_3389_fimmu_2023_1083303 crossref_primary_10_1073_pnas_2110867119 crossref_primary_10_1093_jnci_djab194 crossref_primary_10_1007_s00262_023_03422_6 crossref_primary_10_1016_j_omtm_2024_101212 crossref_primary_10_1111_bjh_20061 crossref_primary_10_1182_blood_2023022682 crossref_primary_10_1080_08830185_2022_2080820 crossref_primary_10_3389_fimmu_2025_1613622 crossref_primary_10_1002_cpt_2631 crossref_primary_10_1093_pcmedi_pbab015 crossref_primary_10_1158_2159_8290_CD_21_1586 crossref_primary_10_1016_j_bbrc_2023_03_024 crossref_primary_10_1172_JCI181893 crossref_primary_10_3389_fimmu_2024_1401683 crossref_primary_10_1016_j_coi_2021_10_001 crossref_primary_10_1038_s41586_022_04494_7 crossref_primary_10_1038_s41591_018_0290_5 crossref_primary_10_1016_j_scib_2025_03_054 crossref_primary_10_1016_j_jcyt_2025_08_007 crossref_primary_10_3390_cancers13184546 crossref_primary_10_3390_cancers15071935 crossref_primary_10_1016_j_ymthe_2025_03_019 crossref_primary_10_1002_adhm_202302425 crossref_primary_10_1073_pnas_2010981117 crossref_primary_10_1080_21645515_2023_2267865 crossref_primary_10_1038_s41586_023_06835_6 crossref_primary_10_1186_s13045_018_0653_x crossref_primary_10_3389_fimmu_2022_913123 crossref_primary_10_1016_j_coi_2021_02_010 crossref_primary_10_1136_jitc_2021_003487 crossref_primary_10_1038_s41571_023_00729_2 crossref_primary_10_3389_fonc_2021_657868 crossref_primary_10_1038_s41551_023_01146_7 crossref_primary_10_1182_blood_2021013895 crossref_primary_10_3389_fimmu_2020_608167 crossref_primary_10_3390_hemato2040043 crossref_primary_10_1158_2326_6066_CIR_20_0236 crossref_primary_10_3390_cancers12010125 crossref_primary_10_1002_ange_202008386 crossref_primary_10_1007_s00281_023_00983_7 crossref_primary_10_1016_j_jcyt_2024_10_001 crossref_primary_10_1208_s12248_025_01017_w crossref_primary_10_1158_1078_0432_CCR_19_0101 crossref_primary_10_1186_s40425_019_0686_x crossref_primary_10_1016_j_ymthe_2020_10_023 crossref_primary_10_1073_pnas_2427216122 crossref_primary_10_3389_fimmu_2022_770132 crossref_primary_10_3390_vaccines12060636 crossref_primary_10_3389_fimmu_2023_1139482 crossref_primary_10_1038_s41467_023_43656_7 crossref_primary_10_3389_fimmu_2019_02310 crossref_primary_10_1097_MOP_0000000000000866 crossref_primary_10_1016_j_jcyt_2024_11_003 crossref_primary_10_1016_j_arr_2025_102715 crossref_primary_10_1016_j_bbmt_2020_06_011 crossref_primary_10_1016_j_tibtech_2021_03_005 crossref_primary_10_1007_s00761_025_01706_3 crossref_primary_10_1016_j_jconrel_2023_01_047 crossref_primary_10_1038_s41416_018_0325_1 crossref_primary_10_3390_ijms26115024 crossref_primary_10_1002_med_21727 crossref_primary_10_1182_bloodadvances_2019000600 crossref_primary_10_1186_s40364_020_00197_1 crossref_primary_10_1016_j_xcrm_2025_102301 crossref_primary_10_3389_fphys_2025_1655306 crossref_primary_10_1186_s13045_022_01255_x crossref_primary_10_1158_2326_6066_CIR_22_0910 crossref_primary_10_1007_s00210_025_04055_5 crossref_primary_10_1182_bloodadvances_2022007891 crossref_primary_10_3389_fimmu_2019_01691 crossref_primary_10_1080_14712598_2019_1595582 crossref_primary_10_3389_fimmu_2020_01787 crossref_primary_10_1186_s13045_020_01001_1 crossref_primary_10_1182_bloodadvances_2022008985 crossref_primary_10_3389_fimmu_2022_850358 crossref_primary_10_1136_jitc_2024_009825 crossref_primary_10_3389_fimmu_2019_00128 crossref_primary_10_3389_fimmu_2022_958960 crossref_primary_10_3390_ijms24119115 crossref_primary_10_1182_blood_2020009309 crossref_primary_10_3390_cancers13020284 crossref_primary_10_1016_j_hlife_2024_06_002 crossref_primary_10_1038_s41375_024_02444_y crossref_primary_10_1111_bjh_15918 crossref_primary_10_3390_cancers14081857 crossref_primary_10_1186_s12967_021_03132_6 crossref_primary_10_1093_nsr_nwae018 crossref_primary_10_1038_s41551_024_01287_3 crossref_primary_10_1126_scitranslmed_abh1962 crossref_primary_10_1158_1078_0432_CCR_23_0178 crossref_primary_10_3389_fimmu_2022_840388 crossref_primary_10_1016_j_biotechadv_2022_107917 crossref_primary_10_1182_bloodadvances_2023011934 crossref_primary_10_1007_s11684_021_0904_z crossref_primary_10_1200_EDBK_280571 crossref_primary_10_1038_s41571_019_0297_y crossref_primary_10_1182_bloodadvances_2023010607 crossref_primary_10_1186_s12929_024_00998_8 crossref_primary_10_3389_fmedt_2022_850565 crossref_primary_10_1007_s10238_020_00628_1 crossref_primary_10_1016_j_apsb_2024_04_022 crossref_primary_10_1016_j_ccell_2023_11_011 crossref_primary_10_1038_s41577_021_00541_y crossref_primary_10_1016_j_ymthe_2025_03_052 crossref_primary_10_1186_s12967_021_03165_x crossref_primary_10_1136_jitc_2021_003441 crossref_primary_10_1158_1078_0432_CCR_20_4746 crossref_primary_10_3389_fimmu_2022_887866 crossref_primary_10_1200_JCO_25_00568 crossref_primary_10_1016_j_transci_2021_103066 crossref_primary_10_1158_2326_6066_CIR_23_1011 crossref_primary_10_1182_blood_2018_09_835389 crossref_primary_10_1016_j_jsbmb_2024_106571 crossref_primary_10_1016_j_tips_2024_03_004 crossref_primary_10_1080_14712598_2020_1738378 crossref_primary_10_1158_2326_6066_CIR_20_0675 crossref_primary_10_1126_science_abq6990 crossref_primary_10_3390_cancers14020299 crossref_primary_10_1080_2162402X_2019_1676615 crossref_primary_10_3389_fimmu_2023_1253395 crossref_primary_10_3390_cancers16142608 crossref_primary_10_1038_s41467_019_13880_1 crossref_primary_10_3389_fimmu_2022_947648 crossref_primary_10_1158_2159_8290_CD_22_1175 crossref_primary_10_1182_blood_2023022861 crossref_primary_10_1186_s12943_021_01363_1 crossref_primary_10_1038_s41375_024_02257_z crossref_primary_10_1038_s41591_020_01157_w crossref_primary_10_1002_ajh_25457 crossref_primary_10_1016_S0007_4551_19_30047_5 crossref_primary_10_1038_s43018_023_00709_6 crossref_primary_10_1007_s00262_023_03537_w crossref_primary_10_1038_s41417_021_00395_5 crossref_primary_10_1136_jitc_2021_003897 crossref_primary_10_1089_genbio_2023_0008 crossref_primary_10_3389_fimmu_2023_1142614 crossref_primary_10_1200_JCO_18_01457 crossref_primary_10_1038_s41571_022_00689_z crossref_primary_10_1038_s43018_025_01009_x crossref_primary_10_1007_s40265_019_01071_7 crossref_primary_10_1016_j_jtct_2024_09_024 crossref_primary_10_1016_j_isci_2024_110863 crossref_primary_10_3389_fonc_2022_1077436 crossref_primary_10_1016_j_ymthe_2022_12_004 crossref_primary_10_3390_ijms251910511 crossref_primary_10_1182_blood_2021011898 crossref_primary_10_1016_j_drudis_2022_06_010 crossref_primary_10_1021_acsnano_4c18391 crossref_primary_10_1016_j_copbio_2019_01_016 crossref_primary_10_1158_2159_8290_CD_21_1508 crossref_primary_10_1038_s41409_024_02463_4 crossref_primary_10_1126_scitranslmed_abg3072 crossref_primary_10_1158_2326_6066_CIR_17_0405 crossref_primary_10_1111_nyas_14724 crossref_primary_10_3390_cancers14225674 crossref_primary_10_1007_s00262_022_03172_x crossref_primary_10_1016_j_jtct_2023_11_014 crossref_primary_10_1080_10428194_2025_2456096 crossref_primary_10_1186_s40425_019_0799_2 crossref_primary_10_1038_s42003_020_1021_2 crossref_primary_10_1002_ajh_25398 crossref_primary_10_1016_j_cellin_2022_100067 crossref_primary_10_1038_s41551_025_01344_5 crossref_primary_10_1155_2020_8765028 crossref_primary_10_1038_s41434_021_00307_0 crossref_primary_10_1038_s44321_024_00024_2 crossref_primary_10_1002_cti2_1373 crossref_primary_10_1016_j_jcyt_2022_01_011 crossref_primary_10_1016_j_omtm_2022_06_010 crossref_primary_10_1080_2162402X_2019_1570774 crossref_primary_10_3389_fimmu_2018_01740 crossref_primary_10_1097_BOR_0000000000001012 crossref_primary_10_1002_anie_202008386 crossref_primary_10_1007_s10529_023_03461_0 crossref_primary_10_1016_j_biomaterials_2019_119302 crossref_primary_10_1111_nyas_14719 crossref_primary_10_3390_ijms20205010 crossref_primary_10_3390_ijms20174315 crossref_primary_10_3389_fimmu_2023_1063454 crossref_primary_10_3390_ijms25073851 crossref_primary_10_1002_hem3_70007 crossref_primary_10_1038_s41568_023_00560_y crossref_primary_10_1016_j_intimp_2024_113166 crossref_primary_10_1016_j_annonc_2020_10_478 crossref_primary_10_1016_j_mattod_2023_02_009 crossref_primary_10_1186_s43556_023_00122_6 crossref_primary_10_1016_j_omto_2023_100728 crossref_primary_10_1002_adhm_202002080 crossref_primary_10_3389_fimmu_2022_878209 crossref_primary_10_1186_s13045_019_0746_1 crossref_primary_10_3389_fonc_2020_565857 crossref_primary_10_1126_sciadv_adp4008 crossref_primary_10_1016_j_molcel_2023_02_026 crossref_primary_10_1186_s12906_022_03660_8 crossref_primary_10_3389_fimmu_2024_1376660 crossref_primary_10_1038_s41467_025_59298_w crossref_primary_10_1182_blood_2024026758 crossref_primary_10_1182_bloodadvances_2020001797 crossref_primary_10_1080_10428194_2020_1761967 crossref_primary_10_3390_ijms24109038 crossref_primary_10_1016_j_yrtph_2021_105064 crossref_primary_10_1097_PPO_0000000000000409 crossref_primary_10_1186_s40164_024_00506_6 crossref_primary_10_3389_fimmu_2022_1004703 crossref_primary_10_1002_cac2_12525 crossref_primary_10_1158_2159_8290_CD_22_0964 crossref_primary_10_1016_j_ymthe_2021_08_003 crossref_primary_10_1002_adbi_202101262 crossref_primary_10_3389_fonc_2024_1398902 crossref_primary_10_1172_JCI129205 crossref_primary_10_1016_j_biopha_2021_111333 crossref_primary_10_1097_HS9_0000000000000988 crossref_primary_10_1172_JCI129206 crossref_primary_10_3390_cancers17030383 crossref_primary_10_1038_s41571_018_0039_6 crossref_primary_10_1016_j_intimp_2024_113392 crossref_primary_10_1186_s40779_023_00503_6 crossref_primary_10_1111_imr_13015 crossref_primary_10_3389_fimmu_2023_1265299 crossref_primary_10_1172_JCI129208 crossref_primary_10_1111_imr_13252 crossref_primary_10_3390_ijms22042150 crossref_primary_10_1016_j_immuni_2025_07_017 crossref_primary_10_1186_s12935_024_03479_y crossref_primary_10_1038_s43018_022_00347_4 crossref_primary_10_1002_adbi_202101018 crossref_primary_10_3389_fphar_2025_1493346 crossref_primary_10_3390_ijms22136665 crossref_primary_10_1002_ajh_27546 crossref_primary_10_3389_fimmu_2023_1121565 crossref_primary_10_1186_s13046_021_02076_5 crossref_primary_10_1038_s41568_024_00755_x crossref_primary_10_3390_vaccines8030447 crossref_primary_10_1097_CCO_0000000000000562 crossref_primary_10_1001_jama_2024_19462 crossref_primary_10_1016_j_jcyt_2024_05_023 crossref_primary_10_1182_blood_2022018905 crossref_primary_10_1016_j_jconrel_2019_12_047 crossref_primary_10_3389_fimmu_2025_1605488 crossref_primary_10_1126_sciimmunol_abh1873 crossref_primary_10_7554_eLife_67660 crossref_primary_10_1016_j_compbiomed_2025_110797 crossref_primary_10_1038_s41591_019_0564_6 crossref_primary_10_3389_fimmu_2022_935465 crossref_primary_10_1089_jir_2021_0057 crossref_primary_10_3390_ijms19061803 crossref_primary_10_1016_j_ccell_2022_11_006 crossref_primary_10_1016_j_ctrv_2022_102443 crossref_primary_10_1016_j_omtn_2024_102137 crossref_primary_10_1158_2159_8290_CD_21_1026 crossref_primary_10_1016_j_jtct_2023_10_012 crossref_primary_10_1002_psp4_12922 crossref_primary_10_3389_fimmu_2024_1335932 crossref_primary_10_1016_j_immuni_2023_09_010 crossref_primary_10_1111_cts_12675 crossref_primary_10_1016_j_clim_2020_108382 crossref_primary_10_1182_blood_2021012811 crossref_primary_10_3390_ijms251910263 crossref_primary_10_1053_j_seminhematol_2020_07_005 crossref_primary_10_3892_ol_2025_15019 crossref_primary_10_7759_cureus_65291 crossref_primary_10_1038_s41591_024_03418_4 crossref_primary_10_1007_s11427_020_1713_9 crossref_primary_10_3389_fimmu_2023_1130442 crossref_primary_10_3390_cancers13061229 crossref_primary_10_1016_j_jcyt_2022_10_012 crossref_primary_10_3389_fimmu_2022_830292 crossref_primary_10_3390_vaccines12121348 crossref_primary_10_1093_jimmun_vkaf047 crossref_primary_10_1016_j_ymthe_2025_01_036 crossref_primary_10_1056_NEJMoa1817226 crossref_primary_10_1053_j_seminhematol_2020_07_002 crossref_primary_10_1136_jitc_2022_005967 crossref_primary_10_1038_s41467_022_32491_x crossref_primary_10_1007_s00210_024_03258_6 crossref_primary_10_1172_JCI126397 crossref_primary_10_1126_scitranslmed_abn7336 crossref_primary_10_4103_1319_2442_390259 crossref_primary_10_1038_s41467_020_20696_x crossref_primary_10_3389_fchem_2021_701427 crossref_primary_10_1093_stcltm_szaf020 crossref_primary_10_3390_cancers13205039 crossref_primary_10_3390_cancers13040743 crossref_primary_10_3389_fimmu_2023_1152498 crossref_primary_10_3390_ijms232214255 crossref_primary_10_1002_jcph_1691 crossref_primary_10_1016_j_jiac_2022_10_012 crossref_primary_10_1038_s41591_022_01726_1 crossref_primary_10_3389_fimmu_2023_1186224 crossref_primary_10_1016_j_jcyt_2024_03_003 crossref_primary_10_1007_s00432_019_02867_6 crossref_primary_10_1007_s13402_024_00940_y crossref_primary_10_1038_s41375_020_01085_1 crossref_primary_10_3389_fonc_2020_00262 crossref_primary_10_3389_fonc_2020_01594 crossref_primary_10_1158_2159_8290_CD_20_0037 crossref_primary_10_3389_fimmu_2021_664329 crossref_primary_10_1016_j_ymthe_2019_10_001 crossref_primary_10_1002_bit_28086 crossref_primary_10_1186_s40164_020_00190_2 crossref_primary_10_1146_annurev_immunol_041015_055318 crossref_primary_10_1038_s43018_023_00573_4 crossref_primary_10_1093_immadv_ltaf001 crossref_primary_10_1038_s41467_024_52503_2 crossref_primary_10_1158_1078_0432_CCR_19_3888 crossref_primary_10_1007_s13402_024_00984_0 crossref_primary_10_1016_j_immuni_2023_09_001 crossref_primary_10_1172_JCI142030 crossref_primary_10_1016_j_jcyt_2024_03_481 crossref_primary_10_1182_blood_2020007445 crossref_primary_10_1182_bloodadvances_2022007057 crossref_primary_10_1097_MOH_0000000000000614 crossref_primary_10_1182_blood_2024024523 crossref_primary_10_1097_MOH_0000000000000615 crossref_primary_10_1136_jitc_2024_009462 crossref_primary_10_1053_j_seminhematol_2024_01_001 crossref_primary_10_1007_s11912_020_0875_2 crossref_primary_10_1038_s41573_020_0077_5 crossref_primary_10_1038_s41571_019_0184_6 crossref_primary_10_1158_2326_6066_CIR_21_0110 crossref_primary_10_1371_journal_pcbi_1009883 crossref_primary_10_1016_j_cell_2024_01_035 crossref_primary_10_3389_fimmu_2022_839097 crossref_primary_10_1007_s11756_023_01326_5 crossref_primary_10_1186_s40779_023_00486_4 crossref_primary_10_3389_fonc_2020_01346 crossref_primary_10_1038_s41392_025_02371_z crossref_primary_10_1016_j_csbj_2019_03_015 crossref_primary_10_1016_j_tranon_2022_101459 crossref_primary_10_3389_fimmu_2023_1101769 crossref_primary_10_1016_j_omtn_2025_102618 crossref_primary_10_3389_fimmu_2021_745109 crossref_primary_10_3390_cells7100155 crossref_primary_10_1038_s41590_023_01470_9 crossref_primary_10_1016_j_ymthe_2022_01_007 crossref_primary_10_1158_2326_6066_CIR_18_0508 crossref_primary_10_3390_cells11101701 crossref_primary_10_3389_fimmu_2023_1166038 crossref_primary_10_1186_s40364_020_00190_8 crossref_primary_10_3389_fonc_2020_568056 crossref_primary_10_1007_s40259_021_00477_8 crossref_primary_10_3390_cancers14133168 crossref_primary_10_1016_j_blre_2018_11_002 crossref_primary_10_1016_j_jaci_2024_12_1066 crossref_primary_10_1016_j_jmoldx_2020_12_004 crossref_primary_10_3389_fimmu_2021_627764 crossref_primary_10_1016_j_ccell_2024_02_016 crossref_primary_10_3389_fimmu_2022_873834 crossref_primary_10_1158_0008_5472_CAN_19_3738 crossref_primary_10_1038_s41375_023_01817_z crossref_primary_10_1182_bloodadvances_2021004453C crossref_primary_10_1002_advs_202302175 crossref_primary_10_1073_pnas_2304319120 crossref_primary_10_1080_14789450_2021_1992276 crossref_primary_10_1200_EDBK_320085 crossref_primary_10_3390_pharmaceutics12020194 crossref_primary_10_1016_j_it_2020_06_008 crossref_primary_10_1136_jitc_2022_005360 crossref_primary_10_1038_s41590_025_02241_4 crossref_primary_10_3389_fimmu_2021_693016 crossref_primary_10_1038_s41375_025_02652_0 crossref_primary_10_3390_cells8050472 crossref_primary_10_1016_j_blre_2024_101241 crossref_primary_10_1002_jhbp_944 crossref_primary_10_3389_fimmu_2022_872756 crossref_primary_10_1002_JLB_5MA0122_474R crossref_primary_10_1186_s12943_023_01783_1 crossref_primary_10_1002_eji_202048825 crossref_primary_10_1089_hum_2021_173 crossref_primary_10_3389_fonc_2022_834002 crossref_primary_10_3390_cells9061337 crossref_primary_10_1097_CM9_0000000000003046 crossref_primary_10_2217_fon_2020_0291 crossref_primary_10_1016_S1773_035X_21_00105_2 crossref_primary_10_15252_emmm_202114297 crossref_primary_10_1016_S2152_2650_20_30475_4 crossref_primary_10_1016_j_bulcan_2021_04_008 crossref_primary_10_1158_2159_8290_CD_23_0010 crossref_primary_10_1200_EDBK_238693 crossref_primary_10_1038_s41598_021_04296_3 crossref_primary_10_1080_10428194_2022_2043299 crossref_primary_10_1016_j_jtct_2023_10_022 crossref_primary_10_1182_blood_2019000017 crossref_primary_10_1016_j_jbc_2025_108386 crossref_primary_10_3389_fonc_2021_796477 crossref_primary_10_1126_sciimmunol_abo3420 crossref_primary_10_1177_2515135520927164 crossref_primary_10_1038_s41590_022_01377_x crossref_primary_10_1038_s41591_022_01959_0 crossref_primary_10_3389_fimmu_2021_702636 crossref_primary_10_1182_bloodadvances_2024014822 crossref_primary_10_1126_sciimmunol_abq3016 crossref_primary_10_1158_0008_5472_CAN_21_2931 crossref_primary_10_1002_mco2_716 crossref_primary_10_1080_1750743X_2024_2408048 crossref_primary_10_3892_or_2021_8121 crossref_primary_10_3390_cancers14030504 crossref_primary_10_1073_pnas_1910844119 crossref_primary_10_1038_s41571_023_00754_1 crossref_primary_10_1016_j_ajpath_2024_04_002 crossref_primary_10_1038_s41409_023_02086_1 crossref_primary_10_1016_j_jcyt_2024_04_072 crossref_primary_10_1038_s41568_020_00323_z crossref_primary_10_1186_s13045_023_01499_1 crossref_primary_10_3390_ijms20235942 crossref_primary_10_1016_j_jcyt_2024_02_025 crossref_primary_10_1007_s40272_020_00413_3 crossref_primary_10_1016_j_apmt_2023_101991 crossref_primary_10_1134_S0026893320010100 crossref_primary_10_1016_j_ajem_2021_08_042 crossref_primary_10_1038_s41591_020_1061_7 crossref_primary_10_1111_bjh_18971 crossref_primary_10_1016_j_bioadv_2022_213151 crossref_primary_10_1080_10428194_2024_2414112 crossref_primary_10_1016_j_cobme_2021_100328 crossref_primary_10_1016_j_annonc_2021_07_018 crossref_primary_10_1038_s41571_023_00832_4 crossref_primary_10_1038_s41587_024_02320_1 crossref_primary_10_1056_NEJMoa2408771 crossref_primary_10_1016_j_medj_2022_05_001 crossref_primary_10_3390_cells10092334 crossref_primary_10_1136_jitc_2023_007803 crossref_primary_10_3389_fimmu_2020_594556 crossref_primary_10_1016_j_biopha_2025_118253 crossref_primary_10_1016_j_cels_2025_101260 crossref_primary_10_1038_s41551_023_01085_3 crossref_primary_10_1038_s41423_020_0470_3 crossref_primary_10_3390_ijms19124118 crossref_primary_10_1016_j_biotechadv_2019_06_010 crossref_primary_10_1038_s43018_024_00768_3 crossref_primary_10_1172_JCI157907 crossref_primary_10_1182_blood_2024024104 crossref_primary_10_1016_j_canlet_2020_12_004 crossref_primary_10_3389_fonc_2019_01237 crossref_primary_10_3389_fonc_2019_00146 crossref_primary_10_3390_cells9061367 crossref_primary_10_1016_j_bulcan_2021_06_006 crossref_primary_10_1158_2159_8290_CD_20_1554 crossref_primary_10_1158_2159_8290_CD_23_1393 crossref_primary_10_1158_2326_6066_CIR_19_0299 crossref_primary_10_3389_fimmu_2023_1110028 crossref_primary_10_7554_eLife_49392 crossref_primary_10_1002_adfm_202100088 crossref_primary_10_1007_s00262_023_03619_9 crossref_primary_10_1111_bjh_70019 crossref_primary_10_1080_08830185_2022_2067154 crossref_primary_10_1111_sji_13273 crossref_primary_10_1136_jitc_2020_001631 crossref_primary_10_1016_j_canlet_2022_01_006 crossref_primary_10_1111_imcb_12254 crossref_primary_10_1136_jitc_2020_001877 crossref_primary_10_1186_s12967_022_03442_3 crossref_primary_10_1007_s11899_021_00615_7 crossref_primary_10_3390_ijms22115536 crossref_primary_10_1021_jacs_9b11622 crossref_primary_10_1080_13543784_2020_1770225 crossref_primary_10_3389_pore_2023_1610914 crossref_primary_10_3390_cancers16203483 crossref_primary_10_3389_fonc_2019_00176 crossref_primary_10_1007_s10875_023_01511_w crossref_primary_10_1016_j_cell_2021_02_019 crossref_primary_10_1016_j_jcyt_2021_05_008 crossref_primary_10_1097_CJI_0000000000000256 crossref_primary_10_1186_s12967_022_03729_5 crossref_primary_10_3389_fimmu_2020_569117 crossref_primary_10_3390_cancers13040598 crossref_primary_10_1007_s11596_019_2118_z crossref_primary_10_1186_s12964_020_00617_7 crossref_primary_10_1016_j_bbmt_2019_12_771 crossref_primary_10_1182_bloodadvances_2024015719 crossref_primary_10_3390_ijms242216325 crossref_primary_10_1158_2326_6066_CIR_21_0501 crossref_primary_10_1016_j_omtn_2024_102308 crossref_primary_10_1038_s41375_024_02392_7 crossref_primary_10_1016_j_critrevonc_2020_103096 crossref_primary_10_1016_j_semcancer_2025_05_010 crossref_primary_10_1146_annurev_cancerbio_061521_082320 crossref_primary_10_3390_ijms23147573 crossref_primary_10_1016_j_ccell_2024_01_002 crossref_primary_10_1016_j_jtct_2020_12_004 crossref_primary_10_3390_pharmaceutics14091762 crossref_primary_10_3389_fmed_2023_1199146 crossref_primary_10_1016_j_cobme_2021_100343 crossref_primary_10_4155_bio_2021_0140 crossref_primary_10_1016_j_jcyt_2024_01_006 crossref_primary_10_1126_scitranslmed_aaw2293 crossref_primary_10_1016_j_cellimm_2021_104314 |
| Cites_doi | 10.1182/blood-2015-11-679134 10.1093/bioinformatics/bts082 10.1093/nar/30.10.e47 10.1182/blood-2013-11-535047 10.1182/blood-2014-09-603670 10.1084/jem.20062363 10.1056/NEJMoa1407222 10.1126/scitranslmed.3002842 10.1038/nm.2446 10.1182/blood-2003-02-0420 10.1073/pnas.1408792111 10.1016/j.immuni.2007.09.006 10.1016/j.immuni.2012.04.006 10.1158/0008-5472.CAN-06-3322 10.4049/jimmunol.0804211 10.1371/journal.pone.0057838 10.1038/nprot.2006.239 10.1172/JCI24480 10.1073/pnas.0907448106 10.1038/nprot.2012.143 10.1093/intimm/10.8.1175 10.1172/JCI85309 10.1016/S0140-6736(14)61403-3 10.1200/JCO.2014.56.2025 10.1038/mt.2009.83 10.4049/jimmunol.0802596 10.1126/scitranslmed.aaf8621 10.1093/bioinformatics/btp616 10.1158/0008-5472.CAN-14-2538 10.1158/1078-0432.CCR-12-1177 10.1126/science.7605428 10.1016/j.immuni.2010.06.014 10.1016/j.immuni.2011.09.016 10.1126/scitranslmed.aac5415 10.1038/sj.gene.6364173 10.1038/nature14468 10.1182/blood-2008-12-195792 10.1016/j.immuni.2016.02.023 10.1182/blood-2008-07-167601 10.1146/annurev-immunol-031210-101324 10.1093/bioinformatics/btu638 10.1172/JCI31184 10.1084/jem.20081398 10.1038/ni.1679 10.1073/pnas.0511137103 10.1158/1078-0432.CCR-15-1527 10.1186/s40425-017-0216-7 10.1038/nature04444 10.1158/1078-0432.CCR-11-0116 10.1182/blood-2002-01-0160 10.1182/blood-2003-01-0095 10.1093/bioinformatics/bts635 10.1038/nprot.2012.016 10.1371/journal.pone.0126159 10.1084/jem.20100637 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2018 COPYRIGHT 2018 Nature Publishing Group Copyright Nature Publishing Group May 2018 The Author(s) 2018. |
| Copyright_xml | – notice: The Author(s) 2018 – notice: COPYRIGHT 2018 Nature Publishing Group – notice: Copyright Nature Publishing Group May 2018 – notice: The Author(s) 2018. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 3V. 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7X7 7XB 88A 88E 88I 8AO 8FD 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. LK8 M0S M1P M2O M2P M7N M7P MBDVC P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U RC3 7X8 5PM |
| DOI | 10.1038/s41591-018-0010-1 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science ProQuest Central (Corporate) Animal Behavior Abstracts Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Toxicology Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest Pharma Collection Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) ProQuest Research Library Science Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals ProQuest SciTech Collection ProQuest Medical Library Animal Behavior Abstracts Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Research Library Prep MEDLINE Research Library Prep |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1546-170X |
| EndPage | 571 |
| ExternalDocumentID | PMC6117613 A572561848 29713085 10_1038_s41591_018_0010_1 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA016520 – fundername: NCI NIH HHS grantid: P01 CA214278 – fundername: NCI NIH HHS grantid: T32 CA009140 – fundername: NCI NIH HHS grantid: R01 CA165206 |
| GroupedDBID | --- .-4 .55 .GJ 0R~ 123 1CY 29M 2FS 36B 39C 3O- 3V. 4.4 53G 5BI 5M7 5RE 5S5 70F 7X7 85S 88A 88E 88I 8AO 8FE 8FH 8FI 8FJ 8G5 8R4 8R5 AAEEF AARCD AAYOK AAYZH AAZLF ABAWZ ABCQX ABDBF ABDPE ABEFU ABJNI ABLJU ABOCM ABUWG ACBWK ACGFO ACGFS ACGOD ACIWK ACMJI ACPRK ACUHS ADBBV ADFRT AENEX AEUYN AFBBN AFKRA AFRAH AFSHS AGAYW AGCDD AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMTXH ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CS3 DB5 DU5 DWQXO EAD EAP EBC EBD EBS EE. EJD EMB EMK EMOBN EPL ESX EXGXG F5P FEDTE FQGFK FSGXE FYUFA GNUQQ GUQSH GX1 HCIFZ HMCUK HVGLF HZ~ IAO IEA IH2 IHR IHW INH INR IOF IOV ISR ITC J5H L7B LGEZI LK8 LOTEE M0L M1P M2O M2P M7P MK0 N9A NADUK NNMJJ NXXTH O9- ODYON P2P PQQKQ PROAC PSQYO Q2X RIG RNS RNT RNTTT RVV SHXYY SIXXV SJN SNYQT SOJ SV3 TAE TAOOD TBHMF TDRGL TSG TUS UKHRP UQL X7M XJT YHZ ZGI ~8M AAYXX AFANA AFFHD AGSTI ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY PQGLB XRW AETEA CGR CUY CVF ECM EIF NFIDA NPM ACMFV 7QG 7QL 7QP 7QR 7T5 7TK 7TM 7TO 7U7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N MBDVC P64 PKEHL PQEST PQUKI PRINS Q9U RC3 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c702t-1d9f7dde19be78fd9a5a0baacf60f8903a2748e3420246670e015b0b468159223 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 1308 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000432126800012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1078-8956 1546-170X |
| IngestDate | Tue Nov 04 02:03:32 EST 2025 Thu Oct 02 18:37:00 EDT 2025 Mon Oct 06 17:54:41 EDT 2025 Fri Oct 03 10:50:41 EDT 2025 Sat Nov 29 14:04:38 EST 2025 Sat Nov 29 11:58:52 EST 2025 Sat Nov 29 10:43:48 EST 2025 Wed Nov 26 11:07:16 EST 2025 Wed Nov 26 11:07:38 EST 2025 Thu May 22 21:25:27 EDT 2025 Thu Apr 03 06:53:42 EDT 2025 Sat Nov 29 06:02:24 EST 2025 Tue Nov 18 20:02:46 EST 2025 Fri Feb 21 02:37:38 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c702t-1d9f7dde19be78fd9a5a0baacf60f8903a2748e3420246670e015b0b468159223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 J.A.F., S.F.L., F.B.J., R.M.Y., N.V.F., B.L.L., D.L.S., E.J.W, J.L.B., D.L.P., C.H.J. and J.J.M. designed the experiments and/or performed analysis. J.A.F., M.Gohil, S.L., A.C.B., Y.W, R.S.O., D.E.A., C.Z., N.W, F.B., C.D., F.C., L.T., H.P, M. Gupta, I.K., L.L., J.X., S.H.K., M.M.D. and A.C.H. performed experiments. E.J.O. and H.B. analyzed RNA-seq. data. I.P.-M. carried out the computational analyses of flow cytometric data. W-T.H. and E.P. performed statistical analyses. J.A.F., C.H.J. and J.J.M. wrote the paper, and all authors contributed to writing and providing feedback. Author contributions |
| ORCID | 0000-0002-7443-7227 0000-0001-6971-8465 0000-0003-0241-3557 0000-0001-6969-0693 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/6117613 |
| PMID | 29713085 |
| PQID | 2037030056 |
| PQPubID | 33975 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6117613 proquest_miscellaneous_2033381883 proquest_journals_2486620548 proquest_journals_2037030056 gale_infotracmisc_A572561848 gale_infotracgeneralonefile_A572561848 gale_infotracacademiconefile_A572561848 gale_incontextgauss_ISR_A572561848 gale_incontextgauss_IOV_A572561848 gale_healthsolutions_A572561848 pubmed_primary_29713085 crossref_citationtrail_10_1038_s41591_018_0010_1 crossref_primary_10_1038_s41591_018_0010_1 springer_journals_10_1038_s41591_018_0010_1 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-01 |
| PublicationDateYYYYMMDD | 2018-05-01 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationTitle | Nature medicine |
| PublicationTitleAbbrev | Nat Med |
| PublicationTitleAlternate | Nat Med |
| PublicationYear | 2018 |
| Publisher | Nature Publishing Group US Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group US – name: Nature Publishing Group |
| References | Vesely, Kershaw, Schreiber, Smyth (CR2) 2011; 29 Jain (CR4) 2015; 125 Kochenderfer (CR11) 2015; 33 Winter (CR50) 2007; 67 Kawalekar (CR12) 2016; 44 Lécuroux (CR24) 2009; 113 Porter (CR6) 2015; 7 Jena (CR52) 2013; 8 Precopio (CR27) 2007; 204 Ahmadzadeh (CR32) 2009; 114 Makkouk, Weiner (CR1) 2015; 75 Blackburn (CR31) 2009; 10 Abbas (CR47) 2005; 6 Kalos (CR5) 2011; 3 Hinrichs (CR14) 2009; 106 Anders, Pyl, Huber (CR42) 2015; 31 Rosenberg (CR17) 2011; 17 Betz, Müller (CR19) 1998; 10 Wherry (CR46) 2007; 27 Herbert, Hochreiter, Wright, Shay (CR55) 2006; 1 Lugli (CR21) 2013; 8 Fraietta (CR39) 2016; 127 Maude (CR7) 2014; 371 Turtle (CR10) 2016; 126 Bangs (CR48) 2009; 182 Fourcade (CR33) 2010; 207 Milone (CR36) 2009; 17 Gattinoni (CR13) 2005; 115 Barber (CR30) 2006; 439 Robinson, McCarthy, Smyth (CR43) 2010; 26 Dunne (CR25) 2002; 100 Lee (CR9) 2015; 385 Brown (CR3) 2014; 123 Grosso (CR34) 2007; 117 Kueberuwa (CR28) 2017; 5 McKinney, Lee, Jayne, Lyons, Smith (CR45) 2015; 523 Wirth (CR18) 2010; 33 Rufer (CR26) 2003; 102 Luckey (CR44) 2006; 103 Ramirez (CR49) 2012; 36 Campia (CR51) 2015; 10 Siegel (CR20) 2011; 35 Bruggner, Bodenmiller, Dill, Tibshirani, Nolan (CR22) 2014; 111 Grosso (CR35) 2009; 182 Dobin (CR40) 2013; 29 Ruella (CR38) 2016; 22 Aghaeepour (CR23) 2012; 28 Gattinoni (CR15) 2011; 17 Jones (CR29) 2008; 205 Turtle (CR8) 2016; 8 Trapnell (CR41) 2012; 7 Laport (CR37) 2003; 102 Radvanyi (CR16) 2012; 18 Kim (CR54) 1994; 266 Cawthon (CR53) 2002; 30 N Aghaeepour (10_CR23) 2012; 28 GG Laport (10_CR37) 2003; 102 MD Robinson (10_CR43) 2010; 26 ML Precopio (10_CR27) 2007; 204 A Makkouk (10_CR1) 2015; 75 JF Grosso (10_CR35) 2009; 182 N Rufer (10_CR26) 2003; 102 DL Barber (10_CR30) 2006; 439 TC Wirth (10_CR18) 2010; 33 E Lugli (10_CR21) 2013; 8 L Gattinoni (10_CR15) 2011; 17 PJ Dunne (10_CR25) 2002; 100 K Ramirez (10_CR49) 2012; 36 AR Abbas (10_CR47) 2005; 6 I Campia (10_CR51) 2015; 10 M Ruella (10_CR38) 2016; 22 S Anders (10_CR42) 2015; 31 OU Kawalekar (10_CR12) 2016; 44 JR Brown (10_CR3) 2014; 123 G Kueberuwa (10_CR28) 2017; 5 MC Milone (10_CR36) 2009; 17 SC Winter (10_CR50) 2007; 67 NW Kim (10_CR54) 1994; 266 DW Lee (10_CR9) 2015; 385 C Lécuroux (10_CR24) 2009; 113 A Dobin (10_CR40) 2013; 29 B Jena (10_CR52) 2013; 8 AM Siegel (10_CR20) 2011; 35 SA Rosenberg (10_CR17) 2011; 17 JN Kochenderfer (10_CR11) 2015; 33 RB Jones (10_CR29) 2008; 205 SC Bangs (10_CR48) 2009; 182 L Gattinoni (10_CR13) 2005; 115 UA Betz (10_CR19) 1998; 10 M Ahmadzadeh (10_CR32) 2009; 114 RV Bruggner (10_CR22) 2014; 111 C Trapnell (10_CR41) 2012; 7 EJ Wherry (10_CR46) 2007; 27 SL Maude (10_CR7) 2014; 371 CJ Luckey (10_CR44) 2006; 103 CJ Turtle (10_CR10) 2016; 126 SD Blackburn (10_CR31) 2009; 10 CJ Turtle (10_CR8) 2016; 8 JA Fraietta (10_CR39) 2016; 127 M Kalos (10_CR5) 2011; 3 EF McKinney (10_CR45) 2015; 523 CS Hinrichs (10_CR14) 2009; 106 RM Cawthon (10_CR53) 2002; 30 LG Radvanyi (10_CR16) 2012; 18 MD Vesely (10_CR2) 2011; 29 BS Herbert (10_CR55) 2006; 1 DL Porter (10_CR6) 2015; 7 JF Grosso (10_CR34) 2007; 117 J Fourcade (10_CR33) 2010; 207 P Jain (10_CR4) 2015; 125 30149852 - Trends Mol Med. 2018 Sep;24(9):729-731 33547459 - Nat Med. 2021 Feb 5 29760506 - Nat Rev Clin Oncol. 2018 Jul;15(7):402-403 29769184 - Cancer Discov. 2018 Jul;8(7):784-785 |
| References_xml | – volume: 127 start-page: 1117 year: 2016 end-page: 1127 ident: CR39 article-title: Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia publication-title: Blood doi: 10.1182/blood-2015-11-679134 – volume: 28 start-page: 1009 year: 2012 end-page: 1016 ident: CR23 article-title: Early immunologic correlates of HIV protection can be identified from computational analysis of complex multivariate T-cell flow cytometry assays publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts082 – volume: 30 year: 2002 ident: CR53 article-title: Telomere measurement by quantitative PCR publication-title: Nucleic Acids Res. doi: 10.1093/nar/30.10.e47 – volume: 123 start-page: 3390 year: 2014 end-page: 3397 ident: CR3 article-title: Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia publication-title: Blood doi: 10.1182/blood-2013-11-535047 – volume: 125 start-page: 2062 year: 2015 end-page: 2067 ident: CR4 article-title: Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib publication-title: Blood doi: 10.1182/blood-2014-09-603670 – volume: 204 start-page: 1405 year: 2007 end-page: 1416 ident: CR27 article-title: Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8 T cell responses publication-title: J. Exp. Med. doi: 10.1084/jem.20062363 – volume: 371 start-page: 1507 year: 2014 end-page: 1517 ident: CR7 article-title: Chimeric antigen receptor T cells for sustained remissions in leukemia publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1407222 – volume: 3 start-page: 95ra73 year: 2011 ident: CR5 article-title: T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia publication-title: Sci. Transl. Med doi: 10.1126/scitranslmed.3002842 – volume: 17 start-page: 1290 year: 2011 end-page: 1297 ident: CR15 article-title: A human memory T cell subset with stem cell-like properties publication-title: Nat. Med doi: 10.1038/nm.2446 – volume: 102 start-page: 1779 year: 2003 end-page: 1787 ident: CR26 article-title: Ex vivo characterization of human CD8 T subsets with distinct replicative history and partial effector functions publication-title: Blood doi: 10.1182/blood-2003-02-0420 – volume: 111 start-page: E2770 year: 2014 end-page: E2777 ident: CR22 article-title: Automated identification of stratifying signatures in cellular subpopulations publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1408792111 – volume: 27 start-page: 670 year: 2007 end-page: 684 ident: CR46 article-title: Molecular signature of CD8 T cell exhaustion during chronic viral infection publication-title: Immunity doi: 10.1016/j.immuni.2007.09.006 – volume: 36 start-page: 921 year: 2012 end-page: 932 ident: CR49 article-title: Gene deregulation and chronic activation in natural killer cells deficient in the transcription factor ETS1 publication-title: Immunity doi: 10.1016/j.immuni.2012.04.006 – volume: 67 start-page: 3441 year: 2007 end-page: 3449 ident: CR50 article-title: Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-3322 – volume: 182 start-page: 6659 year: 2009 end-page: 6669 ident: CR35 article-title: Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells publication-title: J. Immunol. doi: 10.4049/jimmunol.0804211 – volume: 8 year: 2013 ident: CR52 article-title: Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials publication-title: PLoS One doi: 10.1371/journal.pone.0057838 – volume: 1 start-page: 1583 year: 2006 end-page: 1590 ident: CR55 article-title: Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.239 – volume: 115 start-page: 1616 year: 2005 end-page: 1626 ident: CR13 article-title: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 T cells publication-title: J. Clin. Invest. doi: 10.1172/JCI24480 – volume: 106 start-page: 17469 year: 2009 end-page: 17474 ident: CR14 article-title: Adoptively transferred effector cells derived from naive rather than central memory CD8 T cells mediate superior antitumor immunity publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0907448106 – volume: 8 start-page: 33 year: 2013 end-page: 42 ident: CR21 article-title: Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells publication-title: Nat. Protoc. doi: 10.1038/nprot.2012.143 – volume: 10 start-page: 1175 year: 1998 end-page: 1184 ident: CR19 article-title: Regulated expression of gp130 and IL-6 receptor alpha chain in T cell maturation and activation publication-title: Int. Immunol. doi: 10.1093/intimm/10.8.1175 – volume: 126 start-page: 2123 year: 2016 end-page: 2138 ident: CR10 article-title: CD19 CAR-T cells of defined CD4 :CD8 composition in adult B cell ALL patients publication-title: J. Clin. Invest doi: 10.1172/JCI85309 – volume: 385 start-page: 517 year: 2015 end-page: 528 ident: CR9 article-title: T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial publication-title: Lancet doi: 10.1016/S0140-6736(14)61403-3 – volume: 33 start-page: 540 year: 2015 end-page: 549 ident: CR11 article-title: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.2025 – volume: 17 start-page: 1453 year: 2009 end-page: 1464 ident: CR36 article-title: Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo publication-title: Mol. Ther. doi: 10.1038/mt.2009.83 – volume: 182 start-page: 1962 year: 2009 end-page: 1971 ident: CR48 article-title: Human CD4 memory T cells are preferential targets for bystander activation and apoptosis publication-title: J. Immunol. doi: 10.4049/jimmunol.0802596 – volume: 8 start-page: 355ra116 year: 2016 ident: CR8 article-title: Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 and CD4 CD19-specific chimeric antigen receptor-modified T cells publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aaf8621 – volume: 26 start-page: 139 year: 2010 end-page: 140 ident: CR43 article-title: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp616 – volume: 75 start-page: 5 year: 2015 end-page: 10 ident: CR1 article-title: Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-2538 – volume: 18 start-page: 6758 year: 2012 end-page: 6770 ident: CR16 article-title: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1177 – volume: 266 start-page: 2011 year: 1994 end-page: 2015 ident: CR54 article-title: Specific association of human telomerase activity with immortal cells and cancer publication-title: Science doi: 10.1126/science.7605428 – volume: 33 start-page: 128 year: 2010 end-page: 140 ident: CR18 article-title: Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8 T cell differentiation publication-title: Immunity doi: 10.1016/j.immuni.2010.06.014 – volume: 35 start-page: 806 year: 2011 end-page: 818 ident: CR20 article-title: A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory publication-title: Immunity doi: 10.1016/j.immuni.2011.09.016 – volume: 7 start-page: 303ra139 year: 2015 ident: CR6 article-title: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aac5415 – volume: 6 start-page: 319 year: 2005 end-page: 331 ident: CR47 article-title: Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data publication-title: Genes Immun. doi: 10.1038/sj.gene.6364173 – volume: 523 start-page: 612 year: 2015 end-page: 616 ident: CR45 article-title: T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection publication-title: Nature doi: 10.1038/nature14468 – volume: 114 start-page: 1537 year: 2009 end-page: 1544 ident: CR32 article-title: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired publication-title: Blood doi: 10.1182/blood-2008-12-195792 – volume: 44 start-page: 712 year: 2016 ident: CR12 article-title: Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells publication-title: Immunity doi: 10.1016/j.immuni.2016.02.023 – volume: 113 start-page: 3209 year: 2009 end-page: 3217 ident: CR24 article-title: Identification of a particular HIV-specific CD8 T-cell subset with a CD27 CD45RO /RA phenotype and memory characteristics after initiation of HAART during acute primary HIV infection publication-title: Blood doi: 10.1182/blood-2008-07-167601 – volume: 29 start-page: 235 year: 2011 end-page: 271 ident: CR2 article-title: Natural innate and adaptive immunity to cancer publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-031210-101324 – volume: 31 start-page: 166 year: 2015 end-page: 169 ident: CR42 article-title: HTSeq: a Python framework to work with high-throughput sequencing data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu638 – volume: 117 start-page: 3383 year: 2007 end-page: 3392 ident: CR34 article-title: LAG-3 regulates CD8 T cell accumulation and effector function in murine self- and tumor-tolerance systems publication-title: J. Clin. Invest. doi: 10.1172/JCI31184 – volume: 205 start-page: 2763 year: 2008 end-page: 2779 ident: CR29 article-title: Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection publication-title: J. Exp. Med. doi: 10.1084/jem.20081398 – volume: 10 start-page: 29 year: 2009 end-page: 37 ident: CR31 article-title: Coregulation of CD8 T cell exhaustion by multiple inhibitory receptors during chronic viral infection publication-title: Nat. Immunol. doi: 10.1038/ni.1679 – volume: 103 start-page: 3304 year: 2006 end-page: 3309 ident: CR44 article-title: Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0511137103 – volume: 22 start-page: 2684 year: 2016 end-page: 2696 ident: CR38 article-title: The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1527 – volume: 5 start-page: 14 year: 2017 ident: CR28 article-title: CCR7 selected gene-modified T cells maintain a central memory phenotype and display enhanced persistence in peripheral blood in vivo publication-title: J. Immunother. Cancer doi: 10.1186/s40425-017-0216-7 – volume: 439 start-page: 682 year: 2006 end-page: 687 ident: CR30 article-title: Restoring function in exhausted CD8 T cells during chronic viral infection publication-title: Nature doi: 10.1038/nature04444 – volume: 17 start-page: 4550 year: 2011 end-page: 4557 ident: CR17 article-title: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0116 – volume: 100 start-page: 933 year: 2002 end-page: 940 ident: CR25 article-title: Epstein-Barr virus-specific CD8 T cells that re-express CD45RA are apoptosis-resistant memory cells that retain replicative potential publication-title: Blood doi: 10.1182/blood-2002-01-0160 – volume: 102 start-page: 2004 year: 2003 end-page: 2013 ident: CR37 article-title: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34 -selected hematopoietic cell transplantation publication-title: Blood doi: 10.1182/blood-2003-01-0095 – volume: 29 start-page: 15 year: 2013 end-page: 21 ident: CR40 article-title: STAR: ultrafast universal RNA-seq aligner publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – volume: 7 start-page: 562 year: 2012 end-page: 578 ident: CR41 article-title: Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks publication-title: Nat. Protoc. doi: 10.1038/nprot.2012.016 – volume: 10 year: 2015 ident: CR51 article-title: An autocrine cytokine/JAK/STAT-signaling induces kynurenine synthesis in multidrug resistant human cancer cells publication-title: PLoS One doi: 10.1371/journal.pone.0126159 – volume: 207 start-page: 2175 year: 2010 end-page: 2186 ident: CR33 article-title: Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 T cell dysfunction in melanoma patients publication-title: J. Exp. Med. doi: 10.1084/jem.20100637 – volume: 123 start-page: 3390 year: 2014 ident: 10_CR3 publication-title: Blood doi: 10.1182/blood-2013-11-535047 – volume: 17 start-page: 1290 year: 2011 ident: 10_CR15 publication-title: Nat. Med doi: 10.1038/nm.2446 – volume: 207 start-page: 2175 year: 2010 ident: 10_CR33 publication-title: J. Exp. Med. doi: 10.1084/jem.20100637 – volume: 3 start-page: 95ra73 year: 2011 ident: 10_CR5 publication-title: Sci. Transl. Med doi: 10.1126/scitranslmed.3002842 – volume: 44 start-page: 712 year: 2016 ident: 10_CR12 publication-title: Immunity doi: 10.1016/j.immuni.2016.02.023 – volume: 17 start-page: 1453 year: 2009 ident: 10_CR36 publication-title: Mol. Ther. doi: 10.1038/mt.2009.83 – volume: 22 start-page: 2684 year: 2016 ident: 10_CR38 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1527 – volume: 10 year: 2015 ident: 10_CR51 publication-title: PLoS One doi: 10.1371/journal.pone.0126159 – volume: 204 start-page: 1405 year: 2007 ident: 10_CR27 publication-title: J. Exp. Med. doi: 10.1084/jem.20062363 – volume: 111 start-page: E2770 year: 2014 ident: 10_CR22 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1408792111 – volume: 126 start-page: 2123 year: 2016 ident: 10_CR10 publication-title: J. Clin. Invest doi: 10.1172/JCI85309 – volume: 106 start-page: 17469 year: 2009 ident: 10_CR14 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0907448106 – volume: 10 start-page: 1175 year: 1998 ident: 10_CR19 publication-title: Int. Immunol. doi: 10.1093/intimm/10.8.1175 – volume: 75 start-page: 5 year: 2015 ident: 10_CR1 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-2538 – volume: 7 start-page: 303ra139 year: 2015 ident: 10_CR6 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aac5415 – volume: 5 start-page: 14 year: 2017 ident: 10_CR28 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-017-0216-7 – volume: 26 start-page: 139 year: 2010 ident: 10_CR43 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btp616 – volume: 29 start-page: 235 year: 2011 ident: 10_CR2 publication-title: Annu. Rev. Immunol. doi: 10.1146/annurev-immunol-031210-101324 – volume: 127 start-page: 1117 year: 2016 ident: 10_CR39 publication-title: Blood doi: 10.1182/blood-2015-11-679134 – volume: 113 start-page: 3209 year: 2009 ident: 10_CR24 publication-title: Blood doi: 10.1182/blood-2008-07-167601 – volume: 27 start-page: 670 year: 2007 ident: 10_CR46 publication-title: Immunity doi: 10.1016/j.immuni.2007.09.006 – volume: 103 start-page: 3304 year: 2006 ident: 10_CR44 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0511137103 – volume: 523 start-page: 612 year: 2015 ident: 10_CR45 publication-title: Nature doi: 10.1038/nature14468 – volume: 33 start-page: 128 year: 2010 ident: 10_CR18 publication-title: Immunity doi: 10.1016/j.immuni.2010.06.014 – volume: 114 start-page: 1537 year: 2009 ident: 10_CR32 publication-title: Blood doi: 10.1182/blood-2008-12-195792 – volume: 1 start-page: 1583 year: 2006 ident: 10_CR55 publication-title: Nat. Protoc. doi: 10.1038/nprot.2006.239 – volume: 33 start-page: 540 year: 2015 ident: 10_CR11 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.2025 – volume: 36 start-page: 921 year: 2012 ident: 10_CR49 publication-title: Immunity doi: 10.1016/j.immuni.2012.04.006 – volume: 266 start-page: 2011 year: 1994 ident: 10_CR54 publication-title: Science doi: 10.1126/science.7605428 – volume: 18 start-page: 6758 year: 2012 ident: 10_CR16 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1177 – volume: 8 year: 2013 ident: 10_CR52 publication-title: PLoS One doi: 10.1371/journal.pone.0057838 – volume: 385 start-page: 517 year: 2015 ident: 10_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(14)61403-3 – volume: 10 start-page: 29 year: 2009 ident: 10_CR31 publication-title: Nat. Immunol. doi: 10.1038/ni.1679 – volume: 7 start-page: 562 year: 2012 ident: 10_CR41 publication-title: Nat. Protoc. doi: 10.1038/nprot.2012.016 – volume: 182 start-page: 1962 year: 2009 ident: 10_CR48 publication-title: J. Immunol. doi: 10.4049/jimmunol.0802596 – volume: 439 start-page: 682 year: 2006 ident: 10_CR30 publication-title: Nature doi: 10.1038/nature04444 – volume: 100 start-page: 933 year: 2002 ident: 10_CR25 publication-title: Blood doi: 10.1182/blood-2002-01-0160 – volume: 6 start-page: 319 year: 2005 ident: 10_CR47 publication-title: Genes Immun. doi: 10.1038/sj.gene.6364173 – volume: 371 start-page: 1507 year: 2014 ident: 10_CR7 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1407222 – volume: 67 start-page: 3441 year: 2007 ident: 10_CR50 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-3322 – volume: 8 start-page: 33 year: 2013 ident: 10_CR21 publication-title: Nat. Protoc. doi: 10.1038/nprot.2012.143 – volume: 35 start-page: 806 year: 2011 ident: 10_CR20 publication-title: Immunity doi: 10.1016/j.immuni.2011.09.016 – volume: 102 start-page: 1779 year: 2003 ident: 10_CR26 publication-title: Blood doi: 10.1182/blood-2003-02-0420 – volume: 31 start-page: 166 year: 2015 ident: 10_CR42 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btu638 – volume: 115 start-page: 1616 year: 2005 ident: 10_CR13 publication-title: J. Clin. Invest. doi: 10.1172/JCI24480 – volume: 117 start-page: 3383 year: 2007 ident: 10_CR34 publication-title: J. Clin. Invest. doi: 10.1172/JCI31184 – volume: 8 start-page: 355ra116 year: 2016 ident: 10_CR8 publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.aaf8621 – volume: 125 start-page: 2062 year: 2015 ident: 10_CR4 publication-title: Blood doi: 10.1182/blood-2014-09-603670 – volume: 30 year: 2002 ident: 10_CR53 publication-title: Nucleic Acids Res. doi: 10.1093/nar/30.10.e47 – volume: 182 start-page: 6659 year: 2009 ident: 10_CR35 publication-title: J. Immunol. doi: 10.4049/jimmunol.0804211 – volume: 28 start-page: 1009 year: 2012 ident: 10_CR23 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts082 – volume: 102 start-page: 2004 year: 2003 ident: 10_CR37 publication-title: Blood doi: 10.1182/blood-2003-01-0095 – volume: 29 start-page: 15 year: 2013 ident: 10_CR40 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bts635 – volume: 205 start-page: 2763 year: 2008 ident: 10_CR29 publication-title: J. Exp. Med. doi: 10.1084/jem.20081398 – volume: 17 start-page: 4550 year: 2011 ident: 10_CR17 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-0116 – reference: 29760506 - Nat Rev Clin Oncol. 2018 Jul;15(7):402-403 – reference: 33547459 - Nat Med. 2021 Feb 5;: – reference: 29769184 - Cancer Discov. 2018 Jul;8(7):784-785 – reference: 30149852 - Trends Mol Med. 2018 Sep;24(9):729-731 |
| SSID | ssj0003059 |
| Score | 2.7119832 |
| Snippet | Tolerance to self-antigens prevents the elimination of cancer by the immune system
1
,
2
. We used synthetic chimeric antigen receptors (CARs) to overcome... Tolerance to self-antigens prevents the elimination of cancer by the immune system . We used synthetic chimeric antigen receptors (CARs) to overcome... Tolerance to self-antigens prevents the elimination of cancer by the immune system.sup.1,2. We used synthetic chimeric antigen receptors (CARs) to overcome... Tolerance to self-antigens prevents the elimination of cancer by the immune system1,2. We used synthetic chimeric antigen receptors (CARs) to overcome... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 563 |
| SubjectTerms | 631/250/2520 692/53/2423 Animals Antigen receptors, T cell Antigens Antigens, CD19 - metabolism Apoptosis Autoantigens Biomarkers Biomedical and Life Sciences Biomedicine Cancer Cancer Research Care and treatment CD19 antigen CD27 antigen CD8 antigen Cell proliferation Cell therapy Cellular therapy Chimeric antigen receptors Chronic lymphocytic leukemia Cytokines Development and progression Exhaustion Female Genomics Glycolysis Health aspects Immunological memory Immunological tolerance Immunology Immunotherapy Immunotherapy, Adoptive Infectious Diseases Interleukin 6 Interleukin 6 receptors Interleukin-6 - metabolism Letter Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphatic leukemia Lymphocytes Lymphocytes T Male Memory cells Metabolic Diseases Methods Mice Molecular Medicine Neurosciences Patients PD-1 protein Physiological aspects Receptors Receptors, Chimeric Antigen - metabolism Remission Stat3 protein STAT3 Transcription Factor - metabolism T cells Transcription, Genetic Treatment Outcome Tumors |
| Title | Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia |
| URI | https://link.springer.com/article/10.1038/s41591-018-0010-1 https://www.ncbi.nlm.nih.gov/pubmed/29713085 https://www.proquest.com/docview/2037030056 https://www.proquest.com/docview/2486620548 https://www.proquest.com/docview/2033381883 https://pubmed.ncbi.nlm.nih.gov/PMC6117613 |
| Volume | 24 |
| WOSCitedRecordID | wos000432126800012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1546-170X dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M7P dateStart: 19950101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Complete (ProQuest Database) customDbUrl: eissn: 1546-170X dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: 7X7 dateStart: 19950101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1546-170X dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: BENPR dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library (ProQuest Database) customDbUrl: eissn: 1546-170X dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2O dateStart: 19950101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1546-170X dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0003059 issn: 1078-8956 databaseCode: M2P dateStart: 19950101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELfYBogXPsZXYBSDEJ-KlsRp7Dyh0m0CiXVVN1DfIsext4qRjDZF6gt_O3dOGpZqTEhIUZTUF6vOnc_n3M8_E_LCYxnrZty4kdTSRf4SN_UygwrpRsowOCy7_mc-GIjxOB7WH9xmNaxy6ROto84Khd_It4NQRFEAAYZ4f_bDxV2jMLtab6GxRjaQJYFZ6N6w8cRgy3GFORSugInAMqvJxPYMBi7E_PjC9SxAoTUurXrnc8PTKnRyJX9qh6W9W__boNvkZh2Q0l5lQXfIFZ1vkmvVFpWLTXJ9v06-3yW_ds5BZ2hh6LTC12oq8wxvMBQFG6JlQfs7fkzVycTmg6C8RNJPkEEQTTGlr_u90Rt6RDFtQKslYAusUVVUvfR0AUZWqEWJ13r-TX-fyHvky97uUf-jW2_f4CruBaXrZ7Hh4D39ONVcmCyWXemlUioTeUbEHpMwIxaahQHECVHEPQ2hSeqlYSRANxC23CfreZHrh4TKODUmCg0PlA4zJkRmQj_WTIfM04HRDvGWyktUzW2OW2ycJjbHzkRS6TsBfSOKD350yNvmkbOK2OMy4adoEUm1NrVxCkmvyyFkhEmycMhzK4GUGjlido7lfDZLPh18_Qehw1FL6FUtZApog5L1Ogl4E0jV1ZJ82ZI8rojKLxLcagmCB1Ht4qWFJrUHmyWBx3AwgB57cXFjvQ551hRjxQjay3Uxt1UwDAgFc8iDqts0rzqIOURPousQ3upQjQDSnrdL8smJpT-PfJ9DEOqQd8uu9-dv_VWDjy5vxGNyI7C-AJGsW2S9nM71E3JV_Swns2mHrPExt2fRIRsfdgfDEdztBwf2POxYr_Mb5P2Amw |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwGLWmcX3hMm6BwQyCcVO0xE4T5wGhqmVata5Mo6C9BSext4qRjCYF9YWfxG_k-3JjqcbEyx6Q-pDWJ1Zj-7s4Pj4m5KnFY96JPW26UkkT9UvM0Io1dkjHjTSHT6GuP_RGI7G_7-8ukV_1XhikVdY-sXDUcRrhO_IN5gjXZZBgiLfH30w8NQpXV-sjNMphsa3mP2DKlr0Z9KF_nzG2-W7c2zKrUwXMyLNYbtqxrz0watsPlSd07MuOtEIpI-1aWvgWlzBRE4o7DMKX63qWgogZWqHjCgj9DIUOwOVfgDSCiYIquNt4frAdv-Q4ClPAxKNeReViI4NAiRwjW5hWQYhoxcHFaHAiHC5SNRfWa4swuHn9f2vAG-RalXDTbmkhN8mSSlbIpfIIzvkKubxTkQtukZ_9E9Qgmmo6LfnDisokxi-YaoON0Dylvb7t0-hwUqx3QXmOoqaAQZJQOqUvet29l3RMcVmEllvc5lhjVEoR06M5GFEazXO8VrMv6utE3iYfz6Ud7pDlJE3UPUKlH2rtOtpjkXJiLkSsHdtXXDncUkwrg1j1YAmiSrsdjxA5CgoOARdBOb4CGF_IUoQfDfKqueW4FC45C7yGIzAo9942Ti_odjxIiW3hCIM8KRAoGZIgJ-lAzrIsGLz_9A-gD3st0PMKpFN4hkhW-0CgJVCKrIVcbyEPSiH204CrLSB4yKhdXFtEUHnoLGAWx2AHHun04sZaDPK4KcaKkZSYqHRWVMEx4RXcIHdLM22amvkeZIeiYxCvZcANAGXd2yXJ5LCQd3dt24Mk2yCva1P_87f-2oP3z36INXJla7wzDIaD0fYDcpUVfghZu6tkOZ_O1ENyMfqeT7Lpo8KjUfL5vD3Ab85Y1rs |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamARMvXMYtMJhB3FHUxE4T5wGhqqWi2ijVNtDeQuLYW8VIRpOC-sIP49dxTm4s1Zh42QNSH9r61Gqc851zHH_-TMhji8e8G3vadEMVmqhfYkZWrPGGdF2pObwKdf1tbzwW-_v-ZIX8qvfCIK2yjolFoI5Tic_IO8wRrsugwBAdXdEiJoPhm-NvJp4ghSut9XEapYtsqcUPmL5lr0cDuNdPGBu-3eu_M6sTBkzpWSw37djXHgDc9iPlCR37YTe0ojCU2rW08C0ewqRNKO4wSGWu61kKsmdkRY4roAxgKHoA4f-Ch6LlBW1w0mQBwJFf8h2FKWASUq-octHJIGki38gWplWQI1o5cTkznEiNy7TNpbXbIiUOr_7Pg3mNXKkKcdorkXOdrKhknVwqj-ZcrJO19xXp4Ab5OThBGaKpprOSV6xomMT4AUtwwA7NU9of2D6Vh9NiHQzacxQ7BRskD6Uz-rzf23lB9ygul9By69sCe5SlRDE9WgC4UrnI8b2af1Ffp-FN8vFcxuEWWU3SRN0hNPQjrV1He0wqJ-ZCxNqxfcWVwy3FtDKIVTtOICtNdzxa5CgouAVcBKWvBeBryF6ELw3ysvnJcSlocpbxJnpjUO7JbYJh0Ot6UCrbwhEGeVRYoJRIgn50EM6zLBh9-PQPRrs7LaNnlZFO4RpkWO0PgZFAibKW5dOW5UEp0H6a4UbLECKnbDfX6AiqyJ0FzOKYBCFSnd7cIMcgD5tm7BjJiolK50UXHAthwQ1yu4RsM9TM96BqFF2DeC0wNwYo995uSaaHhey7a9seFN8GeVXD_s_f-usdvHv2RWySNQB-sD0ab90jl1kRkpDMu0FW89lc3ScX5fd8ms0eFMGNks_nHQB-A9-733g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Determinants+of+response+and+resistance+to+CD19+chimeric+antigen+receptor+T+cell+therapy+of+chronic+lymphocytic+leukemia&rft.jtitle=Nature+medicine&rft.au=Fraietta%2C+Joseph+A&rft.au=Lacey%2C+Simon+F&rft.au=Orlando%2C+Elena+J&rft.au=Pruteanu-Malinici%2C+Iulian&rft.date=2018-05-01&rft.pub=Nature+Publishing+Group&rft.issn=1078-8956&rft.volume=24&rft.issue=5&rft.spage=563&rft_id=info:doi/10.1038%2Fs41591-018-0010-1&rft.externalDocID=A572561848 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-8956&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-8956&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-8956&client=summon |